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Resumo 
 
Os canabinóides (CBs) podem ser classificados como: fitocanabinóides, os 
constituintes da planta Cannabis sativa L.; canabinóides sintéticos, sintetizados em 
laboratório e os endocanabinóides, que são mediadores lipídicos endógenos. Os 
compostos canabinóides ativam recetores canabinóides – CB1 e CB2. O composto 
psicoativo mais prevalente é o Δ9-tetrahidrocanabinol (THC), mas mais de 60 diferentes 
CBs foram já identificados a partir da planta. Os endocanabinóides (eCBs) melhor 
caracterizados são a anandamida (AEA) e o 2-araquidonoilglicerol (2-AG), que estão 
envolvidos em vários processos biológicos, incluindo plasticidade sináptica, modulação da 
dor, homeostasia energética e reprodução. Por outro lado, alguns canabinóides sintéticos, 
inicialmente projetados para investigação médica, são agora usados como drogas de 
abuso. 
Durante o período de desenvolvimento placentário ocorrem processos de 
remodelação que envolvem proliferação, apoptose, diferenciação e invasão dos 
trofoblastos. Sabe-se que um controlo rigoroso dos níveis de eCBs é necessário para uma 
progressão normal da gravidez e que os eCBs estão envolvidos no turnover celular dos 
trofoblastos. Assim sendo, ao partilharem a ativação dos mesmos recetores, a exposição 
a exocanabinóides, seja pelo uso recreativo ou medicinal, pode levar a alterações nos 
níveis de eCBs e na homeostasia do sistema endocanabinóide (ECS). 
Neste trabalho foi estudado o impacto dos CBs em células trofoblásticas BeWo e em 
culturas primárias de citotrofoblastos humanos. As células foram tratadas durante 24 horas 
com diferentes concentrações de THC, do canabinóide sintético WIN-55,212 (WIN) e de 2-
AG. O tratamento com THC não afetou a viabilidade das células BeWo, enquanto que o 
WIN e o 2-AG causaram uma perda de viabilidade dependente da dose. Estudos 
morfológicos, juntamente com marcadores bioquímicos, indicam que o 2-AG é capaz de 
induzir apoptose em citotrofoblastos. 
Por outro lado, estudos morfológicos realizados com laranja de acridina sugerem que 
a autofagia pode estar envolvida na perda de viabilidade induzida pelo WIN. Todos os 
canabinóides induziram perda de potencial de membrana mitocondrial (Δψm), mas apenas 
o 2-AG levou a um aumento na formação de ROS/RNS, sem terem sido observadas 
  
diferenças nos níveis de glutationa. O stress reticular pode estar envolvido no stress 
oxidativo induzido pelo 2-AG, visto que resultados preliminares apontam para um aumento 
na expressão de CCAAT-enhancer-binding protein homologous protein (CHOP). Para 
além da diminuição da viabilidade celular, os resultados sugerem alterações na progressão 
do ciclo celular. O tratamento com WIN induziu retenção do ciclo celular em fase G0/G1, 
enquanto que o 2-AG levou a uma retenção em fase G2/M. 
Neste trabalho é reforçada a importância da sinalização canabinóide em processos 
importantes de proliferação e morte celular de células trofoblásticas. Visto que as drogas 
canabinóides são as mais consumidas a nível mundial, e umas das drogas recreativas mais 
consumidas pelas mulheres grávidas, este estudo pode contribuir para a compreensão do 
impacto destas substâncias na reprodução humana. 
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Abstract 
 
Cannabinoids (CBs) can be classified as: phytocannabinoids, the constituents of the 
Cannabis sativa plant; synthetic cannabinoids lab-synthesized and the endocannabinoids 
that are endogenous lipid mediators. Cannabinoid compounds activate cannabinoid 
receptors – CB1 and CB2. The most prevalent psychoactive phytocannabinoid is Δ9-
tetrahydrocannabinol (THC), but more than 60 different CBs were already identified in the 
plant. The best characterized endocannabinoids (eCBs) are anandamide (AEA) and 2-
arachidonoylglycerol (2-AG), that are involved in several physiological processes including 
synaptic plasticity, pain modulation, energy homeostasis and reproduction. On the other 
hand, some synthetic cannabinoids that were initially designed for medical research, are 
now used as drugs of abuse.  
During the period of placental development, highly dynamic processes of remodeling 
occur, involving proliferation, apoptosis, differentiation and invasion of trophoblasts.  It is 
known that a tight control of eCBs levels is required for normal pregnancy progression and 
that eCBs are involved in trophoblast cells turnover.  Therefore, by sharing activation of the 
same receptors, exposure to exocannabinoids either by recreational or medicinal use may 
lead to alterations in the eCBs levels and in the endocannabinoid system homeostasis  
In this work, it was studied the impact of CBs in BeWo trophoblastic cells and in 
primary cultures of human cytotrophoblasts. Cells were treated for 24 hours with different 
concentrations of THC, the synthetic cannabinoid WIN‐55,212 (WIN) and 2-AG. Treatment 
with THC did not affect BeWo cells viability while WIN and 2-AG caused a dose-dependent 
viability loss. Morphological studies together with biochemical markers indicate that 2-AG is 
able to induce apoptosis in cytotrophoblasts. On the other hand, morphological studies after 
acridine orange staining suggest that autophagy may take part in WIN-induced loss of cell 
viability. All cannabinoids caused a decrease in mitochondrial membrane potential (Δψm) 
but only 2-AG led to ROS/RNS generation, though no changes in glutathione levels were 
observed. In addition, ER-stress may be involved in the 2-AG induced-oxidative stress, as 
preliminary results point to an increase in CCAAT-enhancer-binding protein homologous 
protein (CHOP) expression. Besides the decrease in cell viability, alterations in cell cycle 
  
progression were observed. WIN treatment induced a cell cycle arrest in G0/G1 phase, 
whereas 2-AG induced a cell cycle arrest in G2/M phase.  
Here it is reinforced the relevance of cannabinoid signaling in fundamental processes 
of cell proliferation and cell death in trophoblast cells. Since cannabis-based drugs are the 
most consumed illicit drugs worldwide and some of the most consumed recreational drugs 
by pregnant women, this study may contribute to the understanding of the impact of such 
substances in human reproduction. 
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1. Cannabinoids and the endocannabinoid system 
 
Cannabinoid compounds can be divided in three types: (a) phytocannabinoids, found 
in the Cannabis sativa L. plant, such as Δ9-tetrahydrocannabinol (THC), (b) the laboratory 
synthesized cannabinoids, the synthetic compounds and (c) endogenous lipid compounds 
called endocannabinoids [1]. Cannabinoids are able to activate cannabinoid receptors, CB1 
and CB2 [2], although they can be ligands of other receptors. 
CB1 receptors are more abundant in the SNC  and mediate the actions of THC, like 
impairments in cognition, memory, learning and motor coordination [3]. CB1 is also 
expressed in other several organs like spleen, tonsils, bladder, small intestine, sympathetic 
nerve terminals, smooth muscle cells and reproductive tissues. CB2 receptors, which share 
only 44% of amino acid sequence homology with CB1 and are evolutionarily divergent [4], 
are primarily found on cells of the immune system, but also found in CNS and reproductive 
organs [5]. 
 
1.1 Phytocannabinoids 
 
Cannabis sativa  has been cultivated throughout human history and the oldest known 
written record on cannabis use dates to 4000 B.C, in ancient China, though it is believed 
that it was cultivated in Mongolia and southern Siberia as far as 12.000 years ago, which 
places the plant among humanity's oldest cultivated crops [6]. The plant has been used for 
a large variety of purposes, as a source of industrial fiber, seed oil, food, paper, clothes, 
recreation and medicine. Vikings and medieval Germans used cannabis for relieving pain 
during childbirth and for toothaches, while India’s traditional medicine has used cannabis 
as an hallucinogenic, hypnotic, sedative, analgesic, and anti-inflammatory agent. Medical 
indications for cannabis included rheumatic pain, intestinal constipation, disorders of the 
female reproductive system, malaria and others [7]. 
Over the last decades there has been a marked increase in cannabis use in 
developed countries including Europe and USA [8] (figure1). The increase in cannabis use 
has raised questions about the extent to which cannabis may have harmful physical or 
psychological effects on users. 
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Figure 1 - Most consumed drugs/alcohol in 2014, from Global Drug Survey, [9] 
 
Marijuana and hashish are derived from cannabis plant. The active components, 
known as “cannabinoids”, are found mainly within the flowers, but also in leaves, stalks, and 
seeds. More than 400 compounds have been identified, including 60 different cannabinoids. 
The first cannabinoids identified, by Mechoulam, Shvo and Gaoni, in 1963 and 1965, 
were THC [10] and Cannabidiol (CBD) [11]. Another phytocannabinoid present in cannabis 
is Cannabinol (CBN), which has no psychoactive effects (figure 2), while THC, the major 
active compound in marijuana, is primarily responsible for its psychoactive effects. 
Nevertheless, the legalization of marijuana for medical use is still a controversial 
issue. Additionally, marijuana is much more powerful today than it was 30 years ago, since 
the average THC levels in plants rose from less than 1% in the mid-1970's to more than 6% 
in 2002 and 12% in 2012 [12].  Due to its sedative, analgesic and anti-inflammatory 
properties [13], indications for medical cannabis use include treatment of nausea and 
vomiting as side effects of cancer treatment [14], poor appetite in AIDS-related wasting [15], 
chronic pain [16] and painful spasms in multiple sclerosis [17], epileptic convulsions [18], 
and glaucoma [19]. To date, for the treatment of chemotherapy-induced nausea and 
emesis, two cannabinoid-based medications have gained approval by the Food and Drug 
Administration - Marinol® (dronabinol), a laboratory synthesized tetrahydrocannabinol [20] 
* denotes all types and preparations 
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and Cesamet® (nabilone), a synthetic cannabinoid analogue of THC [21]. Marinol can be 
prescribed as an appetite stimulant to treat cachexia in cancer and AIDS patients [20]. 
Sativex®, a drug that contains equivalent concentrations of THC and CBD, has been 
approved in many countries to relieve spasticity in multiple sclerosis patients and as an 
adjunctive analgesic treatment for adult patients with advanced cancer [22, 23]. 
 
 
 
Figure 2 - Chemical structure of some phytocannabinoids. Structure of the main 
phytocannabinoid Tetrahydrocannabinol (THC) and other cannabinoid compounds found in the 
cannabis plant, Cannabinol (CNB) and Cannabidiol (CBD). 
 
Many evidences suggest that cannabis use may negatively impact several aspect of 
people’s lives, including mental and physical health, cognitive function, pre- and postnatal 
development among offspring (table 1). Indeed, marijuana is associated with adverse 
psychiatric, cardiovascular, respiratory, and immunologic events. Moreover, marijuana may 
interact with a number of prescription drugs and concomitant disease states [24]. 
Marijuana may exacerbate psychiatric disorders in patients with schizophrenia, 
psychosis, bipolar disorder, depression, eating disorders, or panic and anxiety disorders 
[25]. In addition, marijuana abusers are four times more likely to develop depression than 
people who do not use marijuana [26]. Long-term consumption has been associated with 
respiratory diseases, it may worsen chronic obstructive pulmonary disease, asthma, and 
tuberculosis [27]. In pregnancy, it may impair intrauterine growth and cause structural and 
neurobehavioral alterations in the fetus [28].  
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Table 1 - Possible health effects of cannabis consumption 
      Possible Health Effects 
Short-term Enhanced sensory perception and euphoria followed by 
drowsiness/relaxation; slowed reaction time; problems with 
balance and coordination; increased heart rate and appetite; 
problems with learning and memory; hallucinations; anxiety; 
panic attacks; psychosis. 
Long-term Mental health problems, chronic cough, frequent respiratory 
infections. 
Other Health-related Issues Youth: possible loss of IQ points when repeated use begins 
in adolescence. 
Pregnancy: babies born with problems with attention, 
memory, and problem solving. 
In combination with Alcohol Increased heart rate, blood pressure; further slowing of 
mental processing and reaction time. 
Withdrawal Symptoms Irritability, trouble sleeping, decreased appetite, anxiety. 
 
1.2  Synthetic Cannabinoids 
 
Synthetic cannabinoids (sCBs) are often chemically related to THC and sometimes 
called “synthetic marijuana” or “legal marijuana”, but actually the effects can be considerably 
more powerful, unpredictable and more dangerous [29]. Most of these products have 
particularly long half-lives, which is one of the reasons why their pharmacological effects 
may differ significantly [30]. In fact, sCBs are anything but harmless and were never 
designed for human consumption, but synthesised to investigate potential medical uses of 
cannabis. They are full agonists of the CB receptors, and many of them have higher efficacy 
than THC [31, 32]. There is no published safety data for the majority of compounds, and 
little is known about their effects in humans. Many are controlled substances, but repeatedly 
modifications of the compounds produce new versions not covered by legislation [33]. The 
dangerous drugs are labelled as “Spice”, “K2”, “Blonde”, “Summit”, “Blaze”, “Red Dawn X”, 
“Citron”, “Green Giant”, “Red Giant”, “Keisha Kole”, “Geeked Up” or “Ninja”, for example, 
and marked as incense, herbal mixtures or potpourri in order to mask its true purpose [29]. 
Unfortunately, recent data from Global Drug Survey showed that the consumption of these 
drugs of abuse and the percentage of users in need for emergency medical treatment is 
dangerously rising [9, 34] (figure 3). The use of sCBs is linked with nausea and vomiting, 
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high blood pressure, tremor, hallucinations, paranoia, anxiety, psychosis, seizures, acute 
renal failure and, in some cases, death [29].  
 
 
 
Figure 3 - Percentage of people that had sought emergency medical treatment (EMT) 
following the use of drugs/alcohol in 2015, from Global Drugs Survey [34] 
 
The synthetic cannabinoids fall into three major structural groups: (i) 
Aminoalkylindoles (e.g. JWH-018 and WIN-55,212), the dominant cannabinoid series 
detected in Spice [35]; (ii) Non-classical Cyclohexylphenols (e.g. CP 47,497 and 
homologues); and (iii) Classical cannabinoids (e.g. HU-210) (Figure 4) [36].  
 
 
Figure 4 - Chemical structure of some synthetic cannabinoids. Representative examples.of the 
three classes of synthetic cannabinoids: Classical, Non-classical and Aminoalkylindoles. 
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A recent study about the relation between chemical structure and activity of the 
numerous synthetic cannabinoids concluded that the best predictor of potential 
cannabimimetic effects was the affinity for CB1 receptor [37]. WIN 55,212-2 is one of the 
most widely used analogues of cannabinoids designed to activate both CB1 and CB2 
receptors [38]. It has been demonstrated that CB receptor agonists like WIN produce 
protective effects in the brain, including the WIN-induced reduction of epileptic 
manifestations in rats [39] and the WIN-induced anticonvulsant activity in pentylenetetrazole 
(PTZ)-evoked seizures in rats [40].  
Supporting a modulatory role of synthetic cannabinoids in the toxic events elicited by 
toxic metabolites involved in neurodegeneration, Colín-González et al. reported that, as pre-
treatment, WIN exerted protective effects on the mitochondrial dysfunction, and prevented 
the reactive oxygen species (ROS) formation and lipid peroxidation. These effects were 
induced by endogenous metabolites that accumulate in the brain of children affected by 
severe organic acidemias with neurodegeneration [41]. WIN also increases nociception 
threshold in cholestatic rats. This has implications for the treatment of the pruritus of 
cholestasis since pruritus is a nociceptive stimulus and drugs that increase the threshold to 
nociception may be a novel approach to the treatment of this symptom in patients with liver 
disease [42]. Another study suggests that peripherally-administered WIN may be effective 
in relieving cancer pain since it attenuated tumor-evoked mechanical hyperalgesia by 
activation of both peripheral cannabinoid 1 and cannabinoid 2 receptors [43]. Due to its anti-
inflammatory properties, WIN was also able to reduce the expression of some 
metalloproteinases associated with cartilage degradation in human chondrocytes, 
suggesting a mechanism by which cannabinoids may act to prevent cartilage breakdown in 
arthritis [44]. 
 
1.3   Endocannabinoids 
 
In 1992, almost 30 years after the identification of THC, Devane and collaborators 
identified the first endogenous compound that activates the cannabinoid receptor CB1. This 
compound was N-arachidonoylethanolamide and named as Anandamide (AEA), derived 
from the Indo-european language Sanskrit word “ananda”, which means “internal bliss”  
[45]. Then, in 1993, the second cannabinoid receptor CB2 [46] was found and other 
endocannabinoids have also been identified in the last decades, such as 2-
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arachidonoylglycerol (2-AG, [47]), 2-arachidonyl glyceryl ether (noladin ether, [48]), O-
arachidonoyl ethanolamine (virodhamine, [49]) and N-Arachidonoyl dopamine (NADA, 
[50]). AEA and 2-AG are the best characterised members of the main families of eCBs [51], 
N-acylethanolamides (NAE) and monoacylglycerols (MAG), respectively. The “major” 
endocannabinoids are represented in figure 5. Other substances called endocannabinoid-
like compounds, are endogenously synthetized. Though they are not capable of activating 
the CB receptors [52], they may interfere with eCBs metabolism. Some examples are 
palmitoylethanolamide (PEA) and oleoylethanolamide (OEA), which are present in small 
amounts in almost all mammalian tissues [53].  
 
 
Figure 5 - Chemical structure of the major endocannabinoids 2-AG and AEA, adapted from [54] 
 
The eCBs act as autocrine and paracrine mediators and modulate several cellular 
processes like proliferation, differentiation and apoptosis [55]. The eCBs have different 
affinities for cannabinoid receptors, different pharmacological profile comparing with THC 
and synthetic cannabinoids and can also bind and activate other receptors [56], such as 
transient receptor potential vanilloid 1 (TRPV1) and peroxisome proliferator activated 
receptors family (PPAR). The existence of other CB receptors like G-protein-coupled 
receptor 55 (GPR55), the purported CB3, has been also proposed [56]. The activation of 
the non-selective cation channel TRPV1 by AEA can be the responsible for non-CBs 
mediated cellular effects such as vasodilatation and apoptosis [57]. Contrary to AEA, 2-AG 
seems to be a very week activator of TRPV1. At higher concentrations, AEA can also 
activate the nuclear receptors PPAR-α and PPAR-ϒ [58-60], and 2-AG is capable to 
activate PPAR-ϒ [59]. 
Regarding the “major” eCBs actions, it is already known that AEA is very important in 
processes like modulation in different stages of reproduction, analgesia, muscle relaxation, 
immunosuppression, inflammation, stimulation of appetite, emesis, proliferation, 
differentiation and apoptosis [55, 61], acting also as an endocrine messenger [60]. 2-AG  
seems to be an important messenger in multiple physiological processes of different 
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systems like nervous, immune or cardiovascular, but its exact functions still remain unclear 
[62].  
When activated by the eCBs, the cannabinoid receptors interfere with several 
signalling pathways in order to exert the effects on the several organs and tissues. In the 
neurons, pre-synaptic stimulation of CB1 inhibits the release of neurotransmitters [63]. In 
the liver, stimulation of CB1 leads to an increase in acetyl-coenzyme A carboxylase and 
fatty acids with consequent increase in lipogenesis [64]. On the other hand, activation of 
CB2 seems to mediate immunosuppression effects [65]. Besides, eCB signalling is involved 
with several other physiological and pathophysiological processes, namely memory, pain, 
inflammation, apetite, reproduction, cardiovascular system, and others (figure 6) [66-69]. 
 
  
 
Figure 6 - Physiological and pathophysiologic processes in which eCB are involved. Adapted 
from [70]. 
 
Therapeutic approaches that modulate the endocannabinoid system (ECS) through 
the interference with eCBs levels, instead of the use of exocannabinoids, may be an 
advantage since it preserves the endocannabinoid specificity and limits the secondary 
effects [70]. 
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1.4 Endocannabinoid System  
 
Following the identification and synthesis of THC by Mechoulam and Gaoni in Israel 
(1964) [10], scientists learned a lot about the pharmacology, biochemistry and clinical 
effects of cannabis, but no one really knew how it worked. In 1973, when American 
researchers at Johns Hopkins University identified receptor sites in the brain capable of 
binding with opioids, such as morphine and heroin [71], some scientists expected that the 
discovery of receptor sites for marijuana would soon follow. In fact, 15 years later, a study 
at the St. Louis University School of Medicine revealed that the brain has receptor sites that 
respond pharmacologically to marijuana compounds. A potent THC analogue was 
synthesized, allowing scientists to investigate the precise locations of cannabinoid receptors 
in the brain [72]. The DNA sequence that encodes a THC-sensitive receptor in the rat’s 
brain  and a successful clone of marijuana receptor was announced by Lisa Matsuda in the 
National Academy of Science’s Institute of Medicine meeting in 1990 [73, 74]. The cloning 
of that receptor opened the door for scientists to sculpt molecules that “fit” this receptor and 
develop genetically engineered “knockout” mice that lack this receptor. Then, as referred 
previously, the discovery of the first endogenous cannabinoid compounds and the 
cannabinoid receptors pointed to the existence of an endocannabinoid system (ECS). The 
eCBs, CB receptors, the proteins that transport, synthesizes and degrade them, compose 
the endocannabinoid system (ECS), represented in figure 7.  
eCBs are released from membrane phospholipid precursors through specific 
phospholipases, which are activated “on demand”. Although there are several biosynthetic 
pathways involved in the formation of AEA, the most prominent route engages a 
transacylation by a Ca2+ dependent N-acyltransferase (NAT) to produce N-
arachidonoylphosphatidylethanolamine (NArPE), with the subsequent conversion of this 
lipid into AEA through the activity of a specific phospholipase D (NAPE-PLD). Similar to 
AEA, 2-AG is synthesized in a two-step pathway, which includes a rapid hydrolysis of 
inositol phospholipids by a specific phospholipase C (PLC) to generate 1,2-diacylglycerol 
(DAG), sequentially converted into 2-AG by diacylglycerol lipase (DAGL). Then, the eCBs 
are transported out of the cell by a specific transporter, called endocannabinoid membrane 
transporter (EMT) and, after re-uptake through the same transporter, eCB signalling is 
finished by hydrolysis via fatty acid amide hydrolase (FAAH) or monoacyl glycerol lipase 
(MAGL). For this, hydrolases break the amide bond of AEA to release arachidonic acid and 
ethanolamine. On the other hand, FAAH and more importantly a specific monoacylglycerol 
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lipase (MAGL) transform 2-AG into arachidonic acid and glycerol. Also cyclooxygenase-2 
(COX-2) is able to accept AEA as a substrate, to generate prostaglandin-ethanolamides, 
and can deoxygenate 2-AG to produce prostaglandin-glyceryl esters [54]. 
The studies on the ECS are expanding to the identification of novel endogenous 
ligands, unveil their metabolism, the signalling pathways and their final action, as well as 
their potential for therapeutics. 
 
 
Figure 7 - Endocannabinoid system. The biosynthesis of anandamide (AEA; blue circles), from 
membrane precursors is catalysed by the N-acyltransferase (NAT) followed by N-acyl-
phosphatidylethanolamines-specific phospholipase D (NAPE-PLD). 2-arachidonoylglycerol (2-AG; 
orange circles) synthesis occurs also from membrane precursors but through diacylglycerol lipase 
(DAGL). Endocannabinoids are transported in both directions through cell membrane by diffusion or 
selective transport via the putative endocannabinoid membrane transporter (EMT). In the 
extracellular space can interact with cannabinoid receptors (CBR) or be internalized and degraded. 
AEA is hydrolyzed by fatty acid amide hydrolase (FAAH) into ethanolamine (EtNH2) and arachidonic 
acid (AA) or by an alternative oxidative mechanism, by cyclooxygenase-2 (COX-2) into 
prostaglandin-ethanolamines. 2-AG is hydrolyzed through monoacylglycerol lipase (MAGL) or FAAH 
into glycerol and arachidonic acid, from [54]. 
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2. Cannabinoids and cell fate 
 
2.1  Cannabinoid signalling pathways  
 
Cannabinoid receptors are typical members of the G protein-coupled receptors 
(GPCR) family, and include CB1 and CB2 as the best characterized targets [75]. Their 
ligands bind through the extracellular domain, activating different cellular pathways (figure 
8). The two CB receptors have differences in the affinity of some agonists and antagonists 
and in the activated signalling pathways. The physical association with lipid rafts represents 
another difference between CB receptors. Unlikely CB1, the binding and activation of CB2 
is not dependent on the microarchitecture of the plasma membrane, since no raft 
perturbation was observed on CB2 binding and signalling after the disruption of lipid rafts 
by cholesterol depletion with methyl-beta-cyclodextrin (MCD) [76].  
The activation of cannabinoid receptors by their agonists initiates the transduction of 
cannabinoid signalling. The stimulation of CB receptors triggers Gi/0 proteins [77, 78] 
leading to the initiation of several cellular mechanisms that include adenylyl cyclase (AC) 
inhibition, mitogen-activated protein kinases (MAPKs) activation, modulation of ion 
channels by activation of inward rectifying K+ channels or inhibition of voltage-gated Ca2+ 
channels [79] (figure 8). CB2 receptors do not seem to have a role in the modulation of 
ionic channels [78]. Under Gi/0 inhibition, CB1 but not CB2 may interact with Gs [80] and 
Gq/11 [81]  proteins and consequently lead to different cellular effects. 
Inhibition of AC results in decrease of cAMP levels and, because cAMP is a second 
messenger that stimulates the activity of Protein Kinase A (PKA), the activity of this protein 
decreases [82-84]. However, the isoform of AC expressed in target cells influences the 
response of CB receptors activation – inhibition (AC-I, III, V, VI and VIII) or stimulation (AC-
II, IV and VII) [85]. 
MAPK pathways regulate cellular functions such as proliferation, differentiation and 
apoptosis. The activation of p42/44 MAPKs, also known as Extracellular regulated kinase 
1/2 (ERK1/2), by CB agonists is dependent on Gi/0-coupling and requires the recruitment 
of phosphatidylinositol-3-kinase (PI3K) and protein kinase B (PKB or Akt) [86]. CB1 can 
also activate p38 MAPK and c-Jun N-Terminal Kinases (JNK1, JNK2) [87].  
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Figure 8 - Cannabinoid signalling pathways after activation of CB receptors coupled to G protein. 
The inhibition of AC induces a decrease in cAMP levels, leading to a decrease in PKA activity. 
Activation of CB1 also mediates the stimulation of Akt and FAK. The binding of the adaptor protein 
FAN to CB1 induces ceramide accumulation through the stimulation of SM hydrolysis by Smase. De 
novo synthesis of ceramide may also occur by SPT, from FA and Ser. As a consequence, ceramide 
stimulate ERK. JNK and p38. AC- Adenylyl Cyclase; PKA- Protein Kinase A; SM- Sphingomyelin; 
Smase- Sphingomyelinase; FAN- Factor associated with neutral sphingomyelinase activation; SPT- 
Serinoylpalmitoyltransferase; Ser- Serine; FA- Fatty acid; ERK- Extracellular signal-regulated kinase; 
JNK-c-Jun N-terminal kinases; p38- p38 Mitogen-activated protein kinase; FAK- Focal adhesion 
kinase. 
 
The adaptor protein factor associated with neutral sphingomyelinase activation (FAN), 
interacting with CB1, mediates the interaction of this receptor and sphingomyelinase 
(SMase), the enzyme that hydrolysis sphingosine to ceramide, inducing an acute generation 
of this second messenger. This short-time production of ceramide is related with regulation 
of metabolic functions and occurs via ERK cascade. The stimulation of de novo synthesis 
of ceramide by serine palmitoyltransferase justifies a long term ceramide accumulation as 
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a consequence of the activation of CB1. Such occurrence is responsible for ceramide-
mediated apoptosis, a process where Raf1/MEK/ERK cascade has an important role [88]. 
Activation of CB1 also mediates the stimulation of Akt and Focal Adhesion Kinase 
(FAK). The protein FAK is required during development, since it participates in focal 
adhesion dynamics between cells, promoting cell migration. It may play other roles in the 
cell, including the regulation of the tumor suppressor p53 [89]. Akt has a key role in multiple 
cellular processes such as glucose metabolism, apoptosis, autophagy, cell proliferation, 
transcription and cell migration.  
One of the the most exciting and promising areas of cannabinoid research is the ability 
of these compounds to control the cell survival/death decision, through the induction/arrest 
of proliferation, autophagy and/or apoptosis,  being these effects dependent on factors, like 
concentration, timing of drug delivery and type of cells [90]. 
 
2.2 Cannabinoids and apoptosis 
 
 
2.2.1 Apoptosis 
 
Apoptosis is a programmed cell death in which cells undergo a coordinated 
dismantling of intracellular components without causing damage to the neighbor cells and 
inflammation. This process is involved in various physiological processes including normal 
cell turnover, proper development and functioning of the immune system, embryonic 
development and chemical-induced cell death. Abnormal apoptosis, either diminished or 
excessive, is associated with some disease conditions including neurodegenerative 
diseases, ischemic damage, autoimmune disorders and many types of cancer [91]. Thus, 
the control of the apoptotic-signaling pathways is recognized for its immense therapeutic 
potential and justifies the study of compounds that are able to modulate apoptosis, like 
cannabinoids. 
Caspases are cysteine-proteases essential in apoptosis [92]. Their inactive zymogens 
gain catalytic activity following apoptotic signals. The caspases involved in apoptosis have 
been classified as initiator caspases (caspase-8, -9 and -10) and executioner caspases 
(caspase-3, -6 and -7). Initiator caspases activate executioner caspases that subsequently 
lead to the generation of a cascade of signaling events for the controlled degradation of key 
structural proteins and cellular components. This, results in the morphological hallmarks of 
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apoptosis such as DNA fragmentation, extensive membrane blebbing and separation of the 
fragments into apoptotic bodies [93]. 
Two main apoptotic pathways, recruiting different initiator caspases can be 
distinguished: the extrinsic or death receptor pathway and the intrinsic or mitochondrial 
pathway (figure 9). Both pathways converge into the execution phase, the final stage of 
apoptosis, started by the activation of the execution caspases -3, -6 and -7 with subsequent 
cleavage of various substrates including cytokeratins, poly (ADP-ribose) polymerase 
(PARP), the plasma membrane cytoskeletal protein alpha fodrin, the nuclear mitotic 
apparatus protein (NuMA) and others [94]. Caspase-3 is activated by any of the initiator 
caspases (caspase-8, caspase-9, or caspase-10) and specifically activates the 
endonuclease caspase-activated DNase (CAD), by cleavage of the inhibitor of caspase 
activated DNase (ICAD) [95]. CAD then degrades chromosomal DNA within the nuclei and 
causes chromatin condensation. Caspase-3 also induces cytoskeletal reorganization and 
disintegration of the cell into apoptotic bodies [96], that undergo phagocytic uptake. 
Phospholipid asymmetry and externalization of phosphatidylserine on the surface of 
apoptotic cells is the hallmark of this phase [97].  
 
 
 
Figure 9 - Intrinsic and extrinsic apoptotic pathways, from [98] 
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The extrinsic pathway involves transmembrane receptor-mediated interactions. The 
death receptors are members of the tumor necrosis factor (TNF) receptor superfamily, 
which have death domains [99]. Upon ligand binding, cytoplasmic adapter proteins that 
exhibit corresponding death domains are recruited. The binding of  Fas ligand to Fas 
receptor results in the binding of the Fas-associated protein with death domain (FADD), and 
the binding of TNF ligand to TNF receptor results in the binding of TNF receptor 1-
associated protein with death domain (TRADD) with recruitment of FADD and receptor-
interacting serine/threonine-protein (RIP) [100, 101]. FADD then associates with 
procaspase-8 via dimerization of the death effector domain and a death-inducing signaling 
complex (DISC) is formed, resulting in the auto-catalytic activation of procaspase-8  into 
active caspase-8 [102]. At this stage, either apoptosis is executed or FLICE (FADD-like IL-
1β-converting enzyme)-inhibitory protein (c-FLIP) can bind to FADD and caspase-8, 
inhibiting death receptor mediated apoptosis [103].  
The mitochondrial pathway can be activated by signals involving growth factors, 
hormones and cytokines, radiation, toxins, hypoxia, hyperthermia, viral infections, oxidative 
and reticular stress. All of these stimuli cause changes in the inner mitochondrial membrane 
that results in an opening of the mitochondrial permeability transition pore (MPT), loss of 
the mitochondrial membrane potential (∆ψm) and release of two main groups of pro-
apoptotic proteins, (i) cytochrome c, Smac/DIABLO and the serine protease HtrA2/Omi and 
(ii) apoptosis inducing factor (AIF), endonuclease G and CAD, from the intermembrane 
space into the cytosol [104]. Cytochrome c binds and activates the apoptotic protease-
activating factor 1 (Apaf-1) and procaspase-9, forming an “apoptosome” [105]. 
Smac/DIABLO and HtrA2/Omi are reported to promote apoptosis by inhibiting IAPs 
(inhibitors of apoptosis proteins) [106].  AIF and Endonuclease G, which function in a 
caspase-independent manner, translocate to the nucleus and cause cleavage of nuclear 
chromatin [107, 108]. CAD is subsequently released from the mitochondria and translocate 
to the nucleus after cleavage by caspase-3, leading to DNA fragmentation and a more 
pronounced and advanced chromatin condensation [109]. The control and regulation of 
these apoptotic mitochondrial events occurs through different members of the Bcl-2 family 
of proteins [110]. The Bcl-2 family of proteins control mitochondrial membrane permeability 
and can be either pro-apoptotic (Bax, Bak, Bid, Bad, Bim and Bik) or anti-apoptotic (Bcl-2, 
Bcl-x, Bcl-XL, Bcl-XS and Bcl-w). It is thought that the main mechanism of action of the Bcl-
2 family of proteins is the regulation of cytochrome c release from the mitochondria via 
alteration of mitochondrial membrane permeability. Bad can heterodimerize with Bcl-Xl or 
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Bcl-2, neutralizing their protective effect of inhibition of the release of cytochrome c from the 
mitochondria, promoting cell death. 
The “cross-talk” between the extrinsic and the intrinsic pathways may also occur. For 
example, the mitochondrial damage in the Fas pathway of apoptosis is mediated by the 
caspase-8 cleavage of Bid. Then, cleaved-Bid migrates to mitochondria where it induces 
permeabilization of the outer mitochondrial membrane that is dependent on the pro-
apoptotic proteins Bax and/or Bak, and thus Bid acts as a sentinel for the cooperation of 
both apoptotic pathways [111].  
 
2.2.2 Cannabinoid-induced apoptosis 
 
A growing number of papers are reporting cannabinoid-induced apoptosis in several 
systems. Cannabinoids have been shown to induce apoptotic cell death of C6 glioma cells 
[112], PC-12 pheochromocytoma cells [113], CHP100 human neuroblastoma cells [114] 
and hippocampal neurons [115]. Moreover, in vivo studies performed in rats bearing 
malignant gliomas showed that THC and WIN treatments resulted in an increase in time of 
survival or eradication of the tumors, compared to untreated animals [116]. The implication 
of CB1 receptor was showed in several cells (glioma C6, pheochromocytoma PC-12 and 
hippocampal neurons) and, in the case of C6 glioma cells, the involvement of CB2 was also 
observed [116]. Moreover, vanilloid receptors seem to be involved in AEA-induced 
apoptosis of CHP100 neuroblastoma cells [114]. In the PC-12 cells, AEA induced 
superoxide generation that culminate in caspase-3 activation, leading to apoptosis [113].  
The apoptotic death of glioma cells seems to be dependent on the generation of 
ceramide [117]. In fact, it has been suggested that cannabinoids enhance ceramide 
synthesis de novo via induction of serinoylpalmitoyltransferase (SPT) [118]. In other 
systems, pharmacological inhibition of de novo ceramide synthesis also prevents 
cannabinoid-induced death, as in the case of prostate tumor cells [119].  
Synthetic cannabinoids may induce apoptosis through a caspase-3-dependent 
mechanism, as observed in the mouse forebrain cultures. Moreover, the results indicate 
that the cytotoxicity of synthetic cannabinoids towards primary neuronal cells is CB1-
mediated  [120]. In the case of EL-7402 human hepatocellular carcinoma cells, WIN-
induced apoptosis is executed via up-regulation of Bax and down-regulation of Bcl-2 
expression, alterations in the mitochondrial membrane potential and increase of caspase-
3, -8 and -9 activities [121].  
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Anandamide, in tumorigenic keratinocytes that overexpress COX-2, activated the 
PKR-like ER kinase (PERK), inositol requiring kinase-1 (IRE1), the transcription factor-6 
(ATF6) ER-stress pathways and the ER-stress apoptosis-associated proteins, C/EBP 
homologous protein-10 (CHOP10), caspase-12, and caspase-3. [122]. The same eCB 
induced cytotoxicity against human melanoma cells through a complex mechanism, which 
involves COX-2 and LOX-derived products, CB1 activation and lipid raft modulation [123]. 
In the case of colorectal cancer cells, cannabigerol (CBG), a safe non-psychotropic 
cannabis-derived cannabinoid, promoted apoptosis, stimulated ROS production, 
upregulated CHOP mRNA and reduced cell growth. In addition, in vivo, CBG inhibited the 
growth of xenograft tumours as well as chemically induced colon carcinogenesis [124]. 
Moreover, a study made in multiple myeloma, showed that cannabidiol (CBD) by itself or in 
synergy with the proteasome inhibitor bortezomib (BORT), a commonly used compound in 
the treatment of this malignancy, strongly inhibited growth, arrested cell cycle progression 
and induced cell death by regulating the ERK, AKT and NF-κB pathways [125]. Similarly, in 
chondrocytes, AEA induced activation of caspase-3, -8, and -9, FAK cleavage, inhibition of 
AKT activation, sustained activation of ERK, JNK, and p38 [126]. 
In the reproductive system, AEA induced apoptosis in decidual cells through the 
involvement of ceramide synthesis, p38 activation and mitochondrial disfunction [127]. In 
addition, this eCB also induced apoptosis in human cytrophoblasts and in BeWo cells [128]. 
Moreover, an apoptotic cell death of BeWo cells was reported after 2-AG treatment in BeWo 
cells through the induction of caspase-3/7 and -9 activities, loss of Δψm and increase in 
ROS generation [129]. 
Nevertheless, further investigation is necessary to recognize the specific downstream 
targets involved in cannabinoid-induced apoptosis and of the relative contribution that the 
apoptotic mechanisms may have in vivo. 
 
2.3 Cannabinoids and autophagy 
 
Parts of this point are transcribed from the manuscript “Cannabinoid-induced 
autophagy: protective or death role?”, which full version is included in appendix. 
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2.3.1 Autophagy 
 
Autophagy is an evolutionary conserved catabolic process that targets portions of 
cytoplasm, damaged organelles and proteins for lysosome degradation and it has crucial 
roles in development and disease. In fact, basal autophagy is normal and necessary to 
remove aged and damaged organelles and proteins, thereby acting as a constitutive quality 
control mechanism [130]. It also allows cell-survival in low-nutrient conditions, playing a 
cytoprotective role. This process occurs naturally in the organism [131-133], though when 
excessive or uncontrolled, autophagy is able to induce cell death, process referred to as a 
“type II programmed cell death”, as opposed to “type I programmed cell death” or apoptosis 
[134, 135]. Even in this case, it depends on cell stimuli, such as endoplasmic reticulum (ER) 
stress, genotoxic/ oncogenic stress, compromised apoptosis, growth factor deprivation, 
radiation and/ or drugs. 
There are two main non-selective canonical pathways to reach autophagy: (i) 
microautophagy and (ii) macroautophagy (or just autophagy). Microautophagy involves the 
invagination of the lysosomal membrane, with incorporation and digestion of cytosolic 
proteins and organelles by lysosomes, without the formation of autophagosomes. It ensures 
the turnover of long-lived proteins in basal conditions [136, 137].  On the other hand, 
macroautophagy is responsible for the degradation of soluble proteins and organelles, 
under stress conditions, by the formation of double-membrane vacuoles named 
autophagosomes, which sequester portions of the cytoplasm, that after a fusion with 
lysosomes and the formation of the autolysosome, are digested by lysosomal hydrolases 
[137-139] (Figure 10). Other types of selective autophagy recognize and select for 
degradation of the cargo (subcellular structures), such as mitochondria, peroxisomes, 
ribosomes and protein aggregates. These specific types of autophagy are called mitophagy 
[140, 141], macropexophagy [142, 143] , and chaperone-mediated autophagy [144, 145]. 
Recent studies have elucidated a novel evolutionarily conserved receptor-mediated 
selective autophagy, “ER-phagy”, that regulates the turnover, function and structure of the 
ER [146, 147].  
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Figure 10 - Schematic illustration showing the two main types of autophagy. Macroautophagy, 
with the formation of the autophagosome and microautophagy, involving invagination of lysosome 
membrane. 
 
The autophagic process was first visualized and studied in yeast. This highly 
organized intralysosomal degradation pathway is regulated by a large family of genes, the 
autophagy-related (atg) genes [148-151], which play essential roles at different stages of 
the autophagic process, including induction, vesicle formation and autophagosome 
degradation [152]. Upon autophagic stimulus, autophagy starts with the formation of the 
pre-autophagosome structure [153, 154], that consists of three steps: nucleation, elongation 
and maturation of the phagophore (a membrane derived from ER, trans-Golgi or 
endosomes) [155-159]. The phagophore is characterized by transient recruitment of the Atg 
proteins, and its nucleation requires phosphatidylinositol 3-kinase catalytic subunit type III 
(PI3K III) activation [155] and the formation of a complex with Beclin-1 [160, 161]. The 
elongation process leads to the formation of an Atg12–Atg5–Atg16 complex, the lipidation 
of the microtubule-associated protein 1A/1B-light chain 3 (LC3-I) and its conversion into an 
LC3-phosphatidylethanolamine conjugate (LC3-II), which acts as a structural component 
inserted in the double-membrane, associated with mature autophagosomes [155, 160, 162-
164]. Upon maturation, the autophagosome fuses with late endosomes or lysosomes to 
form the autolysosome, and its content is digested via the endosomal-lysosomal system 
[162, 165] (Figure 11). 
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Figure 11 - Schematic depiction of the molecular mechanism of autophagy. Upon autophagic 
stimulus, autophagy starts with the formation of the pre-autophagosome structure, which consists of 
three steps: nucleation, elongation and maturation of the phagophore. Phagophore formation is 
stimulated by the formation of the PI3KIII/Beclin-1 complex and inhibition of mTORC1. For 
elongation, the Atg5–Atg12-Atg16 conjugation and multimerization of the phagophore occurs. In 
addition, LC3 processing and insertion into the extending phagophore membrane also occurs. Then, 
the maturation of the autophagosome is accompanied by recycling of LC3-II by Atg4 and release of 
the Atg5–Atg12-Atg16 complex. This is followed by fusion of the autophagosome with the late 
endosomes and lysosomes and proteolytic degradation of the engulfed molecules. 
 
Mammalian Beclin-1 is also an important protein for the autophagic process, that acts 
as a platform for the recruitment and activation of the PI3K III complex, essential for the 
initiation of autophagy [161, 162]. Under non-stress conditions, Beclin-1 interacts with the 
Bcl-2 homology domains (BH3) of the anti-apoptotic proteins of the Bcl-2 family to inhibit 
the formation of the Beclin-1/PI3K III complex, a mechanism that prevents activation of 
autophagy [152, 166] [167]. Conversely, the dissociation of Bcl-2 or Bcl-xL from Beclin-1 
activates autophagy in response to nutrient deprivation and other physiological stimuli [152]. 
In addition, the UV radiation resistance-associated gene (UVRAG) [168], the Bax-
interacting factor 1 (Bif-1) [169] and the activating molecule in BECN1-regulated autophagy 
protein 1 (Ambra-1) [170], are activated upon Bcl-2 release from the Beclin-1 complex, 
acting as positive regulators of the interaction between Beclin-1 with PI3K III [162]. 
Phosphatidylinositol 3-kinase catalytic subunit type 1 (PI3K I) is also an important regulator 
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of the first steps of autophagy. It interacts with kinases inducing the phosphorylation of the 
Protein kinase B (Akt). Upon its activation this kinase phosphorylates TSC1/TSC2 protein 
complex that become inactive and unable to inactivate the G protein Rheb. The active form 
of Rheb further activates the mammalian target of the rapamycin complex 1 (mTORC1), 
thus inhibiting autophagy [155, 171].  
In mammalian cells, the protein complex mTORC1 acts as a nutrient/energy/redox 
sensor. This protein complex is formed by the protein mTOR itself and regulatory-
associated proteins [165, 172].  When nutrients and energy are prevalent, mTOR hyper-
phosphorylates Unc-51-Like Kinase (ULK), inhibits the formation of the autophagic-
induction complex, working as a repressor of autophagy [173]. However, under starvation 
conditions, the inhibitory activity of mTOR is rapidly shut down [162]. Moreover, mTOR 
integrates signals that either inhibit autophagy via PI3K/Akt or trigger autophagy via 
activation of adenosine monophosphate-activated protein kinase (AMPK) [165, 174] . Thus, 
the key regulators of mTOR are Akt and AMPK. The kinase Akt is stimulated by growth 
factors to activate mTOR and inhibit autophagy [175], while AMPK is a kinase that is 
activated in response to an energy deficit, with an increased AMP/ATP ratio, increased 
cytosolic Ca2+ concentration or genotoxic stress [176]. Thus, downregulation of Akt is 
associated with low levels of active mTOR, allowing autophagy to occur, whereas AMPK 
activation represses mTOR and, thus, promotes autophagy [155, 165, 177, 178]. 
Autophagy has been demonstrated to be relevant for processes as diverse as 
neurodegeneration, immune function, cancer, ageing and development [152, 179]. Recent 
studies have shown that its role in cell survival represents only a part of its function, since 
autophagy may also contribute to cell death. 
 
2.3.2   Cannabinoid-induced autophagy  
 
The majority of studies about cannabinoid-induced autophagy have been performed 
in tumor models. It has been demonstrated that cannabinoids induce autophagy in various 
types of cancer cell lines, and that, in most cases, this antineoplastic activity is counteracted 
by the inhibition (pharmacological or genetic) of autophagy, suggesting that this process is 
required for the cannabinoid’s antiproliferative action. On the other hand, some studies have 
also found evidence of autophagy in non-tumor cells. 
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It has been demonstrated that CB1 receptor activation affects lysosomal activity and 
degradation of damaged macromolecules. This suggests that it may influence the course 
and onset of brain aging [180]. On the other hand, the activation of CB2 by the synthetic 
cannabinoid HU-308 can alleviate pathogenesis of experimental autoimmune 
encephalomyelitis via activation of autophagy [181]. Moreover, Sativex® reduces tau and 
amyloid deposition in the hippocampus and cerebral cortex, in a mouse model of complex 
neurodegenerative disorders, through the reduction of free radicals, enhancement of 
mitochondrial activity and stimulation of autophagy [182]. Besides its action in 
neurodegenerative diseases, CBD can protect mouse liver cells from acute alcohol-induced 
steatosis through multiple mechanisms including attenuation of alcohol-mediated oxidative 
stress, prevention of JNK/MAPK (c-Jun N-terminal kinase/ mitogen-activated protein 
kinases) activation and increase of autophagy [183]. In reproductive processes, the 
synthetic cannabinoid methanandamide induced, in vivo or in vitro, an autophagic response 
in pre-implantation mouse embryos [184].  
A recent study has shown that CBD, arachidonyl-2'-chloroethylamide (ACEA) and 
AEA induce autophagy in a dose-dependent manner in fully differentiated Caco-2 cells. 
ACEA and AEA induced canonical autophagy through CB1 activation, whereas CBD did 
not require the entire set of Atg proteins and was CB1-independent [185, 186].  
Recent studies carried out in different experimental tumor models have reported 
activation of autophagy as a consequence of cannabinoid treatment. The way that 
cannabinoids interact with cancer cells was found to depend on the tumor system, including 
the type of receptors to which they bind and the consequent activated pathways (Figure 
12).  
Treatment with phytocannabinoids seems to cause an autophagic cell death, in which 
autophagy precedes apoptosis. Salazar et al. (2009) have shown that THC is able to induce 
autophagy-mediated apoptotic cell death. This anti-tumoral action relies, at least in part, on 
the upregulation of several ER stress-related proteins, including TRIB3, allowing autophagy 
to occur [187]. Furthermore, the authors found that THC also induced accumulation of de 
novo-synthesis of ceramide, upregulation of stress-regulated protein p8 and of its 
downstream targets, activating transcription factor 4 (ATF4), CHOP and TRIB3. This 
supports the involvement of ceramide accumulation in cannabinoid-triggered ER stress and 
autophagy.  
 
Cannabinoids impact on pregnancy: effects in trophoblast cells 
 
| Introduction 
 
24 
 
 
Figure 12 - A schematic representation of the proposed mechanisms by which cannabinoids 
induce autophagy, in an independent or receptor-dependent manner. Cannabinoid treatment 
stimulates autophagy mainly via two different mechanisms: activation of AMPK or stimulation of de 
novo synthesis of ceramide, which leads to an ER stress response with an increase in eIF2α 
phosphorylation, upregulation of p8 and its downstream targets such as ATF4, CHOP, TRIB3, 
GRP78 and subsequent inhibition of the Akt/mTORC1 axis. When the increased level in CHOP is 
not accompanied by the increase in GRP78 or TRIB3, it leads to a mitochondrial-dependent 
apoptosis. Stimulation of autophagy by cannabinoids may lead to cell survival, cell death or 
apoptosis. 
 
A study in glioma cells has described the gene expression profile characteristic of 
THC-resistant cells, being the growth factor Mdk (Midkine, also known as neurite growth-
promoting factor 2 - NEGF2), the most strongly associated gene. This growth factor has 
been associated with modulation of proliferation and migration of various types of cancer 
cells and is often overexpressed in malignant tumors, acting as a protective factor against 
cell death [188, 189]. Moreover, a similar resistance mechanism was found to operate in 
pancreatic cancer cells. The cannabinoid-resistant pancreatic cancer cell line PANC-1 
exhibited higher levels of Mdk than the cannabinoid-sensitive pancreatic cancer cell line 
MIA PaCa-2. Mdk silence sensitized cannabinoid-resistant cell lines as well as a primary 
culture of glioma cells to THC-induced autophagy and apoptosis [190]. 
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In breast cancer cells, treatment with CBD induced ER stress and subsequently 
increased phosphorylation of eukaryotic translation initiation factor 2, subunit 1 alpha 
(eIF2α) and decreased phosphorylated mTORC1 levels. The increase in the autophagic 
marker LC3-II was accompanied by an increase in cleaved-PARP (Poly (ADP ribose) 
polymerase 1), indicating a cross-talk between autophagy and apoptosis. The authors found 
that Beclin-1 plays a central role in the induction of CBD-mediated apoptosis since, in 
addition to enhancing the interaction between Beclin-1 and PI3K III, CBD inhibited the 
association between Beclin-1 and Bcl-2. The effects were receptor-independent, causing 
ROS generation, translocation of BID to the mitochondria and activation of the intrinsic 
apoptotic pathway. When the increase of ROS generation is blocked, the apoptosis and 
autophagy processes are prevented. [191]. Very recently it was shown that this cannabinoid 
triggers glioma stem-like cells (GSCs) differentiation by inducing an autophagic process, 
through activation of the transient receptor potential vanilloid 2 (TRPV2). The autophagy 
promoting activity of CBD seemed to be regulated by the AKT/mTOR protein kinase network 
and PTEN could be involved. GSCs are a subpopulation believed to be involved in 
glioblastoma multiforme tumor initiation and acquired chemoresistance. So, CBD-induced 
autophagy acts as a tumor suppressing mechanism. [192]. A study carried out by Armstrong 
et al, using THC and CBD (Sativex®) showed that these cannabinoids led melanoma cells 
to a non-canonical autophagic-mediated apoptotic cell death, inhibiting melanoma viability, 
proliferation and tumor growth. The referred study suggest that cannabinoid treatment may 
be of clinical benefit for metastatic melanoma [193]. 
CB2 receptor activation was indicated as being responsible for the antitumorigenic 
effects of THC and JWH-015, a synthetic cannabinoid, in hepatocellular carcinoma (HCC) 
cell lines and in human HCC xenografts. The TRIB3/Akt/mTORC1 pathway appears to be 
involved. In addition, increased phosphorylation of AMPK seems to be necessary for the 
autophagy-mediated cell death by cannabinoids in HCC cells [194]. More recently, it was 
also shown that pharmacological inhibition of PPAR-ϒ decreased the death effects of 
cannabinoids in HCC cells. Further, downregulation of TRIB3 reduced the expression of 
PPAR-ϒ and induced p62 accumulation [195]. 
Pellerito and his group (2014) have also reported ER stress induction and cell death 
after WIN55,212-2, treatment in colon cancer cell lines. In accordance with the previously 
described studies, the levels of phosphorylated Akt decreased and the levels of TRIB3 and 
CHOP increased. By contrast, Beclin-1 knockdown was ineffective in counteracting these 
effects, confirming that WIN induced a Beclin-1 independent autophagic pathway. In this 
study, however, the involvement of an autophagic process appears to play a pro-survival 
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role against the cytotoxic effects of the drug. Such data provided evidence for a role for 
PPAR-ϒ in cannabinoid signaling, being the expression of this receptor significantly down-
regulated after WIN treatment [196]. 
A recent work performed by the same group has studied the effect of this cannabinoid 
on human osteosarcoma cells. WIN treatment induced G2/M cell cycle arrest, which was 
associated with the induction of the main markers of ER stress, such as CHOP, TRIB3 and 
GRP78 and enhancement of LC3-II, indicating an autophagic response. In correlation with 
the preceding study, no alteration in Beclin-1 levels were observed [197]. 
Due to its antiproliferative effects, cannabinoids are being combined with other 
existing anti-cancer therapies such as temozolomide (TMZ) [198], TNF-alpha-related 
apoptosis-inducing ligand (TRAIL) [197], gemcitabine (GEM) [199] and radiation [200]. 
These studies are of particular relevance to patients using cannabinoid-based drugs to 
improve cancer therapies.  
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3. Cannabinoids and pregnancy 
 
3.1 The human placenta and trophoblast cells 
 
The placenta is a fascinating organ, shared by the mother and the growing fetus in 
which several well balanced phenomena such as cell proliferation, differentiation, invasion 
and apoptosis co-exist [201, 202]. Serving as the interface between the fetal and maternal 
environments, the human placenta is structured as a villous tree and is in direct contact with 
the maternal blood and thus referred to as hemochorial [203].  The placenta is involved in 
the exchange of gases, nutrients and waste products between the mother and the growing 
fetus. Furthermore, serves as an endocrine organ, producing several pregnancy-associated 
hormones and growth factors, which affect pregnancy, metabolism, fetal growth, parturition 
and other functions, and warrants the protection of the fetus from maternal immunity attack 
[204-206].  
Regarding the anatomy (figure 13), the utero-placental unit is composed of both fetal 
and maternal tissue, derived from the chorionic sac and from the endometrium, respectively. 
The fetal part, the chorionic plate, carries the fetal chorionic blood vessels, while the 
maternal part is known as basal plate. The intervillous space comprises the space between 
the chorionic and basal plate and contain the chorionic villi, within which fetal blood is 
separated by only three or four cell layers from maternal blood. This intervillous space is 
completely lined with multinucleated syncytiotrophoblasts, the cells that contact with the 
maternal blood, which enters this space via spiral endometrial arteries, bathes the villi and 
drains back through endometrial veins. The fetal blood, which is oxygen-deficient, passes 
through two umbilical arteries and the branched chorionic arteries to the extensive arterio-
capillary-venous system within the chorionic villi. Then, the oxygenated fetal blood returns 
to the fetus via chorionic veins and umbilical vein [207]. The fetal and maternal side of the 
human placenta are represented in figure 14. 
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Figure 13 - Human placenta anatomy. Adapted from [208]. 
 
  
Figure 14 - Human placenta. Fetal (A) and maternal (B) side of human term placenta 
 
Besides being characterized by the direct contact between maternal blood and 
trophoblast, human placenta is also defined by its highly invasive placentation, reaching 
deep in the pregnant uterus [203], exhibiting the most pronounced infiltration of the 
myometrium among all eutherian mammals [209].  
 
 
B A 
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The first cell differentiation event in mammalian development occurs in the transition 
from the morula to the blastocyst state and leads to the establishment of two distinct cell 
lineages: the trophectoderm (TE) and the inner mass (ICM) (Figure 15). The first is the 
origin of trophoblasts cells, which constitute the epithelial compartment of the placenta; and 
the second gives rise to the embryo.  
 
 
 
Figure 15 - Pre-implantation development. From [210] 
 
During placentation, trophoblast cells differentiate through two major pathways: the 
villous and extravillous pathways (figure 16). In the villous pathway, cytotrophoblast cells 
(CTs) are the ones that reside at the basement membrane of placental villi and separate 
trophoblasts from the underlying mesenchymal villous core, in a continuous turnover. These 
cells undergo apoptosis, differentiate and fuse to form the multinucleated 
syncytiotrophoblasts (ST), which surround the placental villous and, as referred, are in direct 
contact with the maternal blood within the intervillous space (Figure 17 and 18). Placental 
ST are involved in the transport of nutrients and gases from the maternal to the fetal 
circulation and represent the major endocrine unit of the placenta by secreting numerous 
pregnancy-maintaining hormones including chorionic gonadotropin (hCG), human placental 
lactogen (hPL), estrogen and progesterone [211].  
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Figure 16 - Trophoblast differentiation and proliferation  
 
  
Figure 17 - Histological sections of human placenta stained with haematoxylin and eosin. (A) 
original magnification 200x; (B) original magnification 400x. Legend: (a) Decidua; (b) 
Syncytiotrophoblasts; (c) Blood cells; (d) Blood vessels. 
 
In the extravillous pathway, the villous CTs provide a population of progenitor cells 
that acquire an invasive phenotype and differentiate into either (1) interstitial extravillous 
trophoblasts (iEVTs), which invade the maternal decidua and a portion of the myometrium, 
(2) endovascular extravillous trophoblasts (enEVTs), which remodel the maternal 
vasculature, to guarantee appropriate blood flow to the placenta (figure 18), and (3) 
endoglandular extravillous trophoblasts (egEVTs), that invade the uterine glands, orient 
them towards the intervillous space and replace the uterine epithelial cells [203]. 
Other type of trophoblast cells, the trophoblast giant cells, participate in various 
processes essential to a successful pregnancy, including blastocyst implantation, 
remodelling of the maternal decidua, and secretion of hormones that regulate the 
development of both fetal and maternal compartments of the placenta [212].  
a 
b 
c 
d 
A B 
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These differentiation events are tightly controlled by the interplay of oxygen tension, 
transcription factors, hormones, growth factors, and other signalling molecules. Due to 
trophoblast-mediated plugging of the uterine vasculature, early placental development 
occurs in hypoxic environment, coinciding with a peak in trophoblast prolifferation and 
placental growth [213]. This may lead to the assumption that hypoxia could be the main 
trigger of early trophoblast growth and by the end of the first trimester of pregnancy, when 
blood flow is established, normoxia may trigger trophoblast invasion [214]. Various growth 
factors, cytokines and chemokines are thought to regulate EVTs function [215]. There are 
several observations that support the idea that EVTs ability to invade foreign tissue 
underlies an intrinsic program or at least is not dependent on decidua-specific signals [216, 
217]. However, there are also evidences of a pivotal decidua-specific role in the regulation 
of trophoblast invasion [218]. So, it seems that decidual cells may rather represent a 
“gatekeeper” function allowing trophoblats to access maternal tissues and blood supply by 
achieving an accurate balance between under- and over-invasion [203]. 
 
 
Figure 18 - Placental cytotrophoblasts invasion. From [219] 
 
Abnormal placental development, particularly the inadequate invasion of trophoblast 
cells into the uterus and the subsequent failure of the remodelling of maternal spiral arteries, 
with consequent decrease in blood flow to the placenta, is believed to cause pregnancy 
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disorders like miscarriage, preeclampsia or intrauterine growth restriction [220]. Hence a 
better knowledge about human trophoblast invasion is mandatory to improve therapeutic 
intervention. 
 
3.2 Endocannabinoids and pregnancy 
 
Mammalian pregnancy is a complex process, involving oocyte fertilization, a 
preimplantation phase which includes the embryo development and passage through the 
oviduct, then implantation in the uterus, and further development supported by a functional 
placenta. Several studies demonstrate that a tight control of AEA levels are important in 
several stages of gestation (figure 19). In fact, it has been proposed that AEA is a “guardian 
angel” or “gatekeeper” of mammalian reproduction [221]. 
 
 
Figure 19 - Levels of anandamide through the menstrual cycle and gestation. Solid black line 
represent physiological conditions, in which AEA plasma levels are high during follicular phase and 
lower in the luteal phase of the menstrual cycle, as well at the beginning of implantation. Low AEA 
levels are necessary to promote uterine receptivity and pregnancy maintenance. At the time of labor, 
high levels are required for parturition. The red dashed line represent AEA levels under pathological 
conditions, from placentas of pre-eclampsia patients, ectopic and non-viable pregnancies, as well as 
lymphocytes from women who miscarry. From [221]. 
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It was suggested that high plasma levels of AEA are required at pre-ovulation [222], 
whereas low levels are necessary to achieve successful implantation [223]. Several works 
demonstrate that abnormal cannabinoid signalling, either silenced or enhanced, impairs 
embryo transport [224]. By using CB1 knockout mice [225, 226], it has been shown that 
CB1 regulates the oviductal transport of embryos, while CB2 is not involved in this process. 
In addition, CB1 mRNA has been shown to undergo a temporal variation in human Fallopian 
tubes, whereas a low expression has been detected in women with ectopic pregnancy, 
associated with a lower expression in the endometrium [225]. When embryo at the late 
morula or early blastocyst stage enters in the uterus, and differentiates to become 
implantation-competent, low levels of AEA in the uterine luminal epithelium are beneficial, 
because implantation competency requires down-regulation of AEA binding to blastocyst 
CB1 receptors [227, 228] (figure 20). In the uterus, 2-AG showed a similar distribution as 
AEA during early pregnancy, suggesting that this eCB could also take part in the modulation 
of implantation [228].  
 It appears that the positive or negative effect of AEA on reproductive events critically 
depends on a balance between synthesis and degradation, by NAPE-PLD and FAAH, 
respectively. High levels of FAAH were also found in the human villous cytotrophoblast [223] 
and syncytiotrophoblast [229], suggesting that FAAH has a protective role by cleaving AEA 
and preventing its passage at the maternal-fetal interface.  
Evidences of the critical importance of AEA concentrations in implantation were also 
enhanced in studies on embryos exposed to high levels of AEA, showing embryotoxicity, 
reduced trophoblast proliferation and implantation failure [224, 230, 231]. Similarly, women 
undergoing an in vitro fertilization program and achieving successful implantation, were 
found to have low levels of plasma AEA, associated with high levels of FAAH in their 
peripheral lymphocytes [232, 233].  
Studies performed by our group, revealed that cannabinoid signalling plays an 
important role in several pregnancy events such as decidualization and placentation [234]. 
The characterization of the ECS in rat haemochorial placenta [235], the spatio-temporal 
expression patterns of anandamide-binding receptors in rat implantation sites [236], the 
eCBs levels and expression of their metabolizing enzymes during pregnancy [237] support 
a role for the ECS during these periods. In addition, for the first time, 2-AG metabolic 
machinery was characterized in placental trophoblast cells. The results revealed that 2-AG 
induces a decrease in BeWo cells viability [129] and interferes with human cytotrophoblast 
cells syncytialization, through a CB receptor-dependent mechanism [238].  
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Figure 20 - Potential effects of endocannabinoids at the fetomaternal interface. From [234] 
 
In mouse, cannabinoid signaling via CB1 seems to play a role in parturition [239]. 
Moreover, it was observed that genetic loss of CB1 leads to preterm delivery and lower birth 
weight [240]. In humans, prostaglandin production is associated with parturition. Since 
endocannabinoids significantly increase prostaglandin production in human amnion at term,  
cannabinoid signaling may play a role in parturition [241]. In fact, AEA plasma levels 
dramatically increase and are affected by the duration of labor [223].  
In summary, it seems that eCBs levels have the potential to direct human fertility 
towards a positive or negative outcome. Moreover, eCBs levels and/or the activity of their 
metabolic enzymes in human blood may be considered reliable markers of natural and 
assisted reproduction [221]. In fact, the reduced level of FAAH in peripheral blood has been 
recognized as a diagnostic marker of spontaneous miscarriage in healthy women, as well 
as of failure to achieve an ongoing pregnancy after in vitro fertilization (IVF)-embryo transfer 
in women undergoing assisted reproduction cycles. In the same context, detection of AEA 
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in follicular fluid might be a predictor of oocyte maturity [222]. On the other hand, the drop 
of AEA plasma levels that occurs at ovulation, and less during implantation, could be used 
as a biomarker for the proper timing of embryo transfer in IVF protocols, and/or in 
intracytoplasmic sperm injection (ICSI) procedures [233].  
 
3.3 Exocannabinoids and pregnancy 
 
Cannabinoid signaling, as described before, is involved in several stages of 
pregnancy. So, maternal use of exogenous cannabinoids may disrupt the balance of 
cannabinoid signaling and compromise pregnancy outcome [242, 243]. 
Nowadays cannabis preparations are among the illicit drugs most widely used by 
pregnant women. Indeed, the self-reported use during pregnancy is approximately 2,9% in 
the US, and reaches 5% in the UK [244]. Chronic exposure to THC impairs women 
reproductive potential by disrupting the menstrual cycle and suppressing oogenesis. It is 
also associated with adverse pregnancy outcomes including miscarriage, preterm delivery, 
intrauterine growth restriction and reduced birth weight [232]. 
Since the identification of the foetal alcohol syndrome (FAS), there has been an 
enormous increase in the number of clinical and preclinical reports examining the short- 
and long-term effects of maternal drug abuse [245]. In recent years, tests carried out in 
women who regularly use marijuana found trace amounts of THC and cannabidiol (CBD) in 
their reproductive organs [246]. THC is able to cross the placental barrier during gestation 
[247] and, due to its high lipophilicity, it can be stored in fat tissue and be transferred to the 
babies through maternal milk during lactation [248]. Moreover, the slow release of THC from 
lipid-storage compartments and significant enterohepatic circulation contribute to a long 
terminal half-life of THC in plasma, in chronic cannabis users [249]. In a pregnant women 
following heavy, chronic cannabis use, the drug was found in urine testing 3 months after 
the consumption, proving the very slow release of THC [250]. So, the effects for the foetus 
are not restricted to the use during pregnancy, but also to the maternal consumption before 
that.  
THC seems to be able to inhibit human trophoblast cells turnover [251], and thus it 
may interfere with normal placentation. In fact, evidence from a human epidemiological 
study indicates that regular use of cannabis during pregnancy is associated with decrease 
in birth weight [8], which is also associated with preterm delivery. In addition, THC abuse 
during pregnancy may also interfere with synaptogenesis and brain development [252]. 
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Clinical studies reported that children born from women who used cannabis during 
pregnancy may show some developmental alterations in both childhood (defective memory 
and poor verbal skills) and adulthood (impulsivity, delinquency and drug addiction) [248, 
253, 254].  
The effects of maternal use of synthetic cannabinoids during pregnancy is ambiguous 
due to limited studies in human and a relative short history of the drugs [242]. The possibility 
that new synthetic cannabinoids adversely impacts pregnancy outcome should not be 
neglected, since many sCBs have much higher affinity to cannabinoid receptors than the 
other cannabinoid compounds [255]. During pregnancy, and similar to THC, synthetic 
cannabinoids, such as WIN, are able to interfere with neuronal processes. Mereu et al., 
showed in pregnant rats that prenatal exposure to WIN produces memory deficits linked to 
dysfunction in hippocampal long-term potentiation and glutamate release [256]. Later, 
Castelli et al. showed that adult rats prenatally treated with WIN, presented dysregulation 
of the ECS, with affected density, affinity and/or function of the cannabinoid receptors, 
alterations in the AEA levels and activities of the main AEA metabolic enzymes [257]. These 
findings suggest that prenatal exposure to cannabinoid agonists induces long-term 
alterations of the ECS in brain areas involved in learning-memory, motor activity and 
emotional behavior.  
Studies on the effects of THC analogues, endocannabinoids and synthetic 
cannabinoids which act at cannabinoid receptors, may help to better understand the impact 
of cannabinnoids in pregnancy. Moreover, since the ECS is present and already functional 
in early pregnancy and is critically involved in crucial steps of pregnancy, the active 
constituents of cannabis and the synthetic cannabinoids could directly affect this system 
[242, 245].  
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4. Aims 
 
The endocannabinoid system is involved in a wide range of physiological and 
pathological pregnancy-related processes and its components have the potential for being 
used as biomarkers for reproduction. However, the effects of cannabinoids upon 
placentation and the implicated mechanisms are still under study. Maternal consumption 
either by recreational or medicinal use of cannabinoids leads to a placental exposure. This 
may cause disturbances on the endocannabinoid system homeostasis, ultimately 
culminating in pregnancy complications. Thus, with this study it is pretended to investigate 
the influence of different types of cannabinoids in trophoblasts, by using the BeWo 
cytotrophoblast cell model and primary cultures of cytotrophoblasts and to contribute to the 
knowledge about the role of the ECS and impact of its deregulation in reproductive events, 
specifically in placental development.
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1. Materials 
 
Dulbecco’s Modified Eagle Medium: fetal bovine serum (FBS), antibiotic–
antimycotic solution (penicillin G sodium, streptomycin sulphate and amphotericin B), 
trypsin, 3,3′-dihexyloxacarbocyanine iodide (DiOC6) were from Gibco/Invitrogen 
Corporation, Carlsbad, CA, USA. Antibody anti-CHOP (GADD 153), β-tubulin and rabbit 
IgG were from Santa Cruz Biotechnology. Nitrocellulose membranes and Percoll were 
from GE Healthcare, Chalfont St Giles, Bucks, UK. The Super Signal West Pico 
Chemiluminescence Detection Kit was from Pierce, Rockford, IL, USA, and X-ray films 
were from Kodak XAR, Eastman Kodak. Nutrient Mixture F-12 (DMEM/F12), DNAse, 
paraformaldehyde, Mayer's haematoxylin solution, protease inhibitor cocktail, Triton X-
100, methylthiazolyldiphenyl-tetrazolium bromide (MTT), Höechst 33342, staurosporine 
(STS), carbonyl cyanide m-chlorophenylhydrazone (CCCP), 2,7-
dichlorodihydrofluorescein diacetate (DCDHF-DA), H2O2, glutathione reductase from 
baker’s yeast, β-Nicotinamide adenine dinucleotide 2′-phosphate reduced tetrasodium 
salt hydrate (NADPH), 5,5′-Dithiobis(2-nitrobenzoic acid) (DTNB) and Acridine Orange 
(AO) were from Sigma–Aldrich Co. St. Louis, MO, USA. Ethanol, isopropanol and 
methanol were from Fisher Scientific, Loughborough, UK. DMSO was from VWR, 
Fontenay-sous-Bois, France. Z-VAD-FMK was from BD PharMingen, San Diego, CA, 
USA. Aquamount medium was from BDH Laboratory Supplies, Poole, England. WIN, 2-
AG, AM251 and AM630 were from Tocris Bioscience, Bristol, UK. THC was from Lipomed 
AG, Swiss.  CytoTox 96 Non-Radioactive Cytotoxicity Assay Kit and Caspase-Glo 3/7 
were from Promega. Giemsa was from Merck. Ninety-six-well white plates were from 
Thermo Scientific, Roskilde, Denmark. Ninety-six-well black plates were from BD 
Biosciences, Erembodegem, Belgium.  
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2. Cell cultures 
 
2.1 BeWo cell line 
 
BeWo is a human choriocarcinoma cell line [258], well-accepted as a 
cytotrophoblast cell model. This line was obtained from the American Type Culture 
Collection (ATCC, Manassas, VA, USA).  
BeWo cells were maintained in culture in DMEM/F12 medium supplemented with 
10% (v/v) of FBS and 1% (v/v) of an antibiotic-antimycotic (AB-AM) solution and were 
incubated at 37 °C in 95% air/5% CO2 humidified atmosphere. Culture medium was 
changed at every 3 days. After reaching about 80% of confluence, cells were successively 
sub-cultured to new culture flasks. For this, cells were treated with 0.25% trypsin/EDTA 
1 mM for 3 minutes at 37ºC, washed with PBS and collected to centrifuge tubes with 
culture medium containing 10% FBS (v/v) to inactivate trypsin. Cells were centrifuged at 
600 g for 5 minutes at 4ºC. Then cells were counted in a Neubauer chamber and cultured 
using the cell densities: 1,5x104 cells/well (final volume 200 µL) for 96-well plate, 8x104 
cells/well (final volume 500 µL) for the 24-well plate and 6x105 (final volume 2000 µL) for 
the 6-well plate. After adherence (12 hours), the cells were washed with PBS and treated 
with the compounds, in cell culture medium with 1% (v/v) FBS. 
 
2.2 Isolation and primary cultures of human cytotrophoblasts  
 
Term placentas of normal pregnancies (38-40 weeks of gestation), from Caucasian 
women living in the Porto region, were immediately collected after spontaneous delivery 
or elective caesarean section, from Centro Materno-Infantil do Norte - Centro Hospitalar 
do Porto. All the procedures were conducted in accordance with the Ethical Committee 
of Centro Hospitalar do Porto, Porto. Cytotrophoblast cells were isolated as described 
previously [259, 260]. Briefly, placentas were washed with saline solution to remove most 
of the blood. Then, the villous tissue dissected from at least 10 different regions in the 
whole placenta. The major blood vessels were discarded by fine dissection. Then, the 
tissue was subjected to a chemical digestion in a solution of trypsin and DNAseI. 
Afterwards, the resulting cells were separated in a discontinuous Percoll gradient. After 
centrifugation (600 g, 10 minutes), the cytotrophoblasts were collected, counted and 
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seeded with the adequate densities: for the 96-well plates were seeded 1,35x105 
cells/well (final volume 200 µL); for the  24-well plates were seeded 1x106 (final volume 
500 µL) and for the 6-well plates were seeded 4,5x106 cells/well (final volume 2000 µL). 
The cells were incubated in DMEM/F12 medium supplemented with 10% (v/v) of 
FBS and 1% (v/v) of AB-AM solution at 37 °C in 95% air/5% CO2 humidified atmosphere. 
After adherence (12 hours), the cells were washed with PBS, incubated with DMEM/F12 
medium supplemented with 1% FBS and 1% AB-AM and treated with the compounds, for 
24 hours. 
 
3.  Cell viability assays 
 
To access cell viability it was used the tetrazolium salt [3-(4,5-dimetylthiazol-2-yl)-
2,5-dipheniltetrazolium bromide] (MTT) assay and measured the activity of the enzyme 
lactate dehydrogenase (LDH) in cell culture medium. For that, BeWo cells were plated in 
96-well plates. After 12 hours for adhesion, the medium was replaced with DMEM/F12 
medium with 1% FBS and 1% AB-AM solution in the presence or absence of the 
cannabinoids (1-50 µM), and the cells were incubated for 24 hours. The yellow tetrazole 
MTT (final concentration: 0,5  mg/mL) was added, and the cells were incubated for 3 hours 
at 37 °C. The formed purple formazan was dissolved in a solution of DMSO:isopropanol 
(3:1) and spectrophotometrically quantified at 540  nm by using a Multiskan Ascent 
microplate reader. MTT assay relies on the mitochondrial metabolism for the conversion 
of the yellow dye MTT on a purple dye formazan by viable cells (figure 21). 
 
Figure 21 - Schematic illustration of MTT assay. The MTT dye is converted into the purple 
formazan salt by the mitochondrial reductase enzymes of viable cells. 
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 Lactate dehydrogenase (LDH) is a cytosolic enzyme that is only released from cells 
into the extracellular space when the plasma membrane is disrupted. So, the release of 
LDH into the culture medium was evaluated by measurement of LDH activity by the use 
of the CytoTox 96 Non-Radioactive Cytotoxicity Assay Kit according to the manufacturer's 
instructions. Released LDH activity is measured with a coupled enzymatic assay, which 
results in conversion of a tetrazolium salt (INT) into a red formazan product. Released 
LDH catalyzes the reaction of NAD+ and lactate to pyruvate and NADH, then NADH plus 
INT, in the presence of diaphorase, is catalyzed to NAD+ and the red formazan product. 
The amount of color formed is proportional to the number of lysed cells (figure 22). 
Generation of Formazan is monitored by measuring absorbance at 490 nm. Visible 
wavelength absorbance data were collected using a BioTek Power Wave XS plate 
reader. 
 
Figure 22 - Schematic illustration of LDH assay. Released LDH catalyzes the reaction of NAD+ 
and lactate to pyruvate and NADH, then NADH plus INT, in the presence of diaphorase, is 
catalyzed to NAD+ and the red formazan product.  
 
All the experiments were performed in triplicate in at least three independent 
experiments and results were expressed as percentage of control/untreated cells. 
 
4. Morphological studies 
 
The morphological alterations caused by cannabinoids treatment were evaluated 
by phase-contrast microscopy, Giemsa, Höechst and Acridine Orange (AO) staining.  
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The cells were cultured in 24-well culture plates with coverslips and treated with the 
different cannabinoids (50 µM of THC, 2 µM of WIN, 10 µM of 2-AG) for 24 hours. Cells 
were observed under a phase contrast microscope (Eclipse 400, Nikon, Japan) equipped 
with an image analysis software Nikon NIS Elements. 
Giemsa staining is a variant of the Romanowsky-type stain. This technique allows 
the evaluation of cell morphology. Giemsa contains a mixture of methylene blue, eosin 
and Azure B (methylene azure B). The eosin Y dye stains the basic components of the 
cells. The methylene blue and azure B dyes stain the acidic components in shades 
between blue and purple. Cells were washed with PBS and fixed with methanol for 10 
minutes at 4ºC. Then cells were washed with PBS and stained with Giemsa stain solution, 
diluted in distilled water (1:10) for 30 minutes. After washing with tap water, the coverslips 
with the stained cells were dehydrated and mounted in DPX mounting medium and 
observed under a bright field microscope (Eclipse E400, Nikon, Japan) equipped with 
image analysis software LeicaQwin. 
Höechst is a dye that emits blue fluorescence when bound to DNA. This staining 
allows the evaluation of nuclear morphology and the identification of apoptotic nuclei, 
which present chromatin’s condensation and fragmentation. After fixation with 4% 
paraformaldehyde solution for 15 minutes at 4ºC, the cells were exposed to 0.5  µg/mL 
Höechst 33342 (in PBS) for 20  minutes, washed with PBS, mounted in Fluoroshield 
mounting medium and observed under a fluorescence microscope equipped with an 
excitation filter with maximum transmission at 360/400  nm (Eclipse CI, Nikon, Japan). 
Images were processed by Nikon NIS Elements Image Software. 
Acridine Orange (AO) is a cationic, lipophilic, fluorochrome stain capable of 
permeating cell and organelle membranes, though, once protonated, these dyes tend to 
become trapped on the low pH side of the membrane barrier leading to their accumulation 
in acidic organelle structures, such as phagosomes and lysosomes. At the end of the 
incubation time with the cannabinoids, cells were incubated with AO at 0.1 µg/mL for 15 
min at 37ºC, washed three times with PBS, mounted in PBS and visualized immediately 
in a fluorescence microscope equipped with an excitation filter with maximum 
transmission at 360/400  nm (Eclipse CI, Nikon, Japan). Images were processed by Nikon 
NIS Elements Image Software. 
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5. Mitochondrial membrane potential (∆ψm) 
 
For measure the mitochondrial membrane potential, cells were seeded in a 96-well 
black plate, pre-incubated for 30 minutes with the CB1 and CB2 antagonists, AM251 (1 
µM) and AM630 (1 µM), respectively, and treated with the cannabinoids (25/50 µM of 
THC, 2 µM of WIN, 10 µM of 2-AG) for 24 hours. The cells were then washed with a 
PBS/sucrose 100  mM/protease inhibitor (PI) cocktail and incubated with a 100  nM 
dihexyloxacarbocyanine iodide (DiOC6) solution for 20  minutes at 37 °C in the dark. 
DiOC6 is a fluorescent lipophilic cationic dye, which will accumulate into the mitochondrial 
membrane matrix space in inverse proportion to ∆ψm. A more polarized mitochondria 
(hyperpolarized, where the interior is more negative) will accumulate more dye, and 
depolarized mitochondria accumulate less dye. Then, the DiOC6 solution was removed 
to eliminate the background fluorescence, the PBS/sucrose/PI solution was added to the 
cells and the fluorescence was measured by the use of a Microplate Fluorimeter (BioTek 
Instruments Winooski, VT, USA) (excitation: 488  nm; emission: 525  nm). For the positive 
control, the cells were incubated with the mitochondrial membrane-depolarizing agent 
CCCP (10  μM) for 15  minutes, at 37 °C, before incubation with DiOC6. The results are 
expressed as a percentage, comparing the loss of mitochondrial membrane potential of 
cannabinoid-treated cells with the untreated cells.  
 
6. Reactive oxygen and nitrogen species 
 
For the quantification of reactive oxygen species (ROS) and/or reactive nitrogen 
species (RNS) generated after treatment with cannabinoids, cells seeded in a black 96-
well plate were incubated with the probe 2’-7’-Dichlorodihydrofluorescein (DCDHF-DA) 
for 1 hour at room temperature. After the probe incubation time, cells were pre-treated for 
30 minutes with the CB1 and CB2 antagonists, AM251 (1 µM) and AM630 (1 µM), 
respectively, and then the cannabinoids (50 µM of THC, 1/5 µM of WIN, 10 µM of 2-AG) 
were added and incubated for 1 hour. Inside the cell, the probe is hydrolyzed by esterases 
into DCDHF, which will be oxidized to the fluorescent molecule Dichlorofluorescein 
(DCF), by free ROS and RNS (figure 23).  Fluorescence, proportional to the cellular 
levels of ROS/RNS, was measured using the Microplate Fluorimeter (BioTek 
Instruments) (excitation: 485±10  nm; emission: 530±12.5  nm). The stress inducer H2O2 
(200  μM) was used as a positive control, by incubation for 20 minutes at room 
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temperature. The results are expressed as a percentage, comparing generation of 
ROS/RNS of cannabinoid-treated cells with the untreated cells.  
 
 
Figure 23 - Schematic illustration of the measurement of ROS/RNS generation. Inside the 
cell, the probe DCDHF-DA is hydrolyzed by esterases into DCDHF. Then, DCDHF is oxidized to 
the fluorescent molecule DCF, by free ROS and RNS.   
 
 
7. Glutathione assay 
 
Glutathione plays a critical role in the cellular defense against oxidative and 
nitrosative stress in mammalian cells. Glutathione exists in reduced (GSH) and oxidized 
(GSSG) forms. Reduced glutathione (GSH) is a major tissue antioxidant that provides 
reducing equivalents for the glutathione peroxidase (GPx) catalyzed reduction of lipid 
hydroperoxides to their corresponding alcohols and hydrogen peroxide to water. In the 
GPx catalyzed reaction, the formation of a disulfide bond between two GSH molecules 
gives rise to oxidized glutathione (GSSG). The enzyme glutathione reductase (GR) 
recycles GSSG to GSH with the simultaneous oxidation of ß-nicotinamide adenine 
dinucleotide phosphate (ß-NADPH2). To measure the level of total glutathione (GSSG + 
GSH) of the sample it was used a kinetic assay in which catalytic amounts of glutathione 
cause a continuous reduction of 5,5′-dithiobis-(2-nitrobenzoic) acid (DTNB) to TNB. The 
oxidized glutathione formed is recycled by glutathione reductase and NADPH. The 
product, TNB, is assayed colorimetrically at 412 nm. This reaction is used to measure the 
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reduction of GSSG to GSH and the rate of the reaction is proportional to the GSH and 
GSSG concentration. To measure the levels of GSSH, GSH was masked by pretreatment 
with 2-vinylpyridine (2-VP) (figure 24).  
For this assay, BeWo cells were seed in a 6-well plate and treated with the 
cannabinoid 2-AG for 24 hours. At the end of incubation time, cells were first 
deproteinized with an HClO4 5% acid solution, scrapped and collected to an Eppendorf. 
After centrifugation (6000 g, 5 minutes, 4ºC), both glutathione forms were measured in 
the supernatant and the total amount of protein was quantified, after addition of NaOH 
0,5 M to the pellet, by Lowry method. The results were expressed by the total protein 
content. 
 
Figure 24 - Schematic illustration of glutathione assay. Total glutathione of the sample was 
measured used a kinetic assay in which catalytic amounts of glutathione cause a continuous 
reduction of DTNB to TNB. The oxidized glutathione formed is recycled by glutathione reductase 
and NADPH. The product, TNB, is assayed colorimetrically at 412 nm. To measure the levels of 
GSSH, GSH was masked 2-VP. 
 
 
8. Western Blot 
 
To detect changes in CHOP expression levels after cannabinoid treatment, it was 
performed a western blot technique. 
BeWo cells and CTs were seeded in 6-well plates, pre-incubated for 30 minutes 
with the CB1 and CB2 antagonists, AM251 (1 µM) and AM630 (1 µM), respectively, and 
treated with the compounds for 24 hours. After the incubation period, RIPA buffer (50 mM 
Tris-HCl pH 7.4, 1% NP-40, 0.5% Na-deoxycholate, 0.1% SDS, 50 mM Tris, 150 mM 
NaCl, 2 mM EDTA, 50 mM NaF) plus a cocktail of protease inhibitor (1:100) was added 
to each well, and incubated on ice for 10 minutes. Then, the cells were scrapped, 
collected to an Eppendorf, subjected to three cycles of freezing/thawing and centrifuged 
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at 14 000  g for 10  minutes at 4 °C. Total protein concentrations were measured by 
Bradford assay. 
Protein samples (30 µg) were prepared in sample buffer, denatured by boiling for 3 
minutes, subjected to SDS–polyacrylamide (10%) and transferred onto nitrocellulose 
membranes for 45 minutes in a semi dry transfer system (Trans-Blot SD semi dry transfer 
cell, Bio-Rad). After blocking non-specific binding sites with blocking buffer (5% of dry 
milk in PBS with Triton X-100, 0.1%), the membranes were incubated with the primary 
antibody anti-CHOP (1:100) overnight at 4 °C. Then, after washed with PBS 0.1% Triton, 
the membranes were incubated for 1 hour, at room temperature, with peroxidase-
conjugated secondary antibody anti-rabbit (1:1000). Finally, the blots were analysed 
using a chemiluminescence detection kit and exposed to X-ray films. The membranes 
were then stripped and reincubated with anti-β-tubulin (1:500) for a loading control.  
 
9. Caspase 3/7 activity 
 
To detect caspase 3/7 activity, the cells were seeded in a 96-well white plate pre-
incubated for 30 minutes with the CB1 and CB2 antagonists, AM251 (1 µM) and AM630 
(1 µM), respectively, and treated with the cannabinoids for 24  hours. At the end of the 
incubation time, Caspase-Glo 3/7 reagent was added to the cells according to the 
manufacturer's instructions. The plate was incubated at room temperature for 1 hour and 
the resultant luminescence was measured in relative light luminescence units (RLU) 
using the 96-well Microplate Luminometer (BioTek Instruments, Winooski, VT, USA) 
(figure 25). A negative control assay was conducted by co-incubation with a pan-caspase 
inhibitor, Z-VAD-FMK (10  μM), and a positive control assay was conducted using 
Staurosporine (0.1 μM), which was added 12  hours before the end of the experiment. 
The results are expressed as a percentage, comparing caspase 3/7 activity of 
cannabinoid-treated cells with the untreated cells. 
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Figure 25 - Schematic illustration of caspase 3/7 detection assay. 
 
10.  Cell cycle analysis  
 
BeWo cells were seeded in 6-well plates and treated as described. After 24 hours 
of treatment cells were tripsinized, washed with PBS, resuspended in 0.5 mL of PBS and 
fixed with 4.5 mL of cold ethanol 70%, on ice, for at least 24 hours. After this step, cells 
were centrifuged at 600 g and washed with PBS to remove the fixative solution. Then, 
400 µL of a DNA staining solution [5 µg/mL Propidium Iodide (PI), 0.1% Triton X-100 and 
200 µg/mL Dnase-free Rnase A in PBS] was added to the pellet and the cells were 
incubated overnight at 4ºC and protected from light. After this, samples were filtered and 
DNA content was analysed by flow cytometry based on the acquisition of 40 000 events 
(with a threshold of 100 000) in a BD Accuri™ C6 (Becton-Dickinson, San Jose, CA, USA) 
equipped with BD Accuri C6 software. Detectors for the three fluorescent channels (FL-
1, FL-2, FL-3) and forward (FSC) and side (SSC) light scatter were set on a linear scale. 
Debris, cell doublets and aggregates were gated out and the singlet cells were analysed 
using a two-parameter plot of FL-2-Area to FL-2-Width of PI fluorescence. The 
antiproliferative effect was indicated by the percentage of cells in G0/G1, S and G2/M 
phases of the cell cycle. Data was analysed using BD Accuri C6 software. Assays were 
performed in triplicate in three independent experiments. Results are expressed as 
percentage of total cells in each cell cycle phase. 
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11. Statistical analysis 
 
Statistical analysis was carried out by ANOVA, followed by the Tukey post hoc test 
to make pairwise comparisons of individual means when significance was indicated 
(GraphPad PRISM v. 6.0, GraphPad Software, Inc., San Diego, CA, USA). The results 
are the mean of at least three independent experiments carried out in triplicate. Data are 
expressed as the mean±SEM, and differences were considered to be statistically 
significant at P<0.05. 
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1. Cannabinoid effects in BeWo cells  
 
1.1 Cell viability assays 
 
In order to investigate the impact of cannabinoids in BeWo cells viability, it was 
compared the effects of the CB agonists THC, WIN and 2-AG. 
In previous works from the group, it was observed that 2-AG decreased cell viability 
in a dose-dependent manner [129]. In that way, it was investigated THC and WIN effects 
by using different concentrations (1-50 µM) for 24 hours. 
To analyze the effects on cell viability, it was performed the MTT assay and measured 
the activity of the enzyme LDH released in cell culture medium.  
The phytocannabinoid THC did not seem to cause changes in cell viability (figure 
26). 
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Figure 26 - Effect of THC on BeWo cells viability. Cell viability of THC-treated cells with different 
concentrations (10-50 µM) at 24 hours of treatment, assessed by (A) MTT assay and (B) LDH 
release. Results are expressed as mean ± SEM of at least three independent experiments performed 
in triplicate. 
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WIN induced a decrease in cell viability dependent on the concentration of the 
compound. The MTT results showed that 2 µM of WIN induced a decrease of 16% in cell 
viability, though no significant release of the cytoplasmic LDH was observed (figure 27).  
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Figure 27 - Effect of WIN on BeWo cells viability. Cell viability of WIN-treated cells with different 
concentrations (1 - 50µM) at 24h of treatment, assessed by (A) MTT assay and (B) LDH release. 
Results are expressed as mean ± SEM of at least three independent experiments performed in 
triplicate. Significant differences between control and treated cells are denoted as *(p<0.05), ** 
(p<0.005) and *** (p<0.0005). 
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1.2 Morphological studies 
 
To investigate whether the different cannabinoids induced morphological alterations, 
BeWo cells were treated for 24 hours with each compound, observed under a phase 
contrast microscope and stained with Giemsa and Höechst.  
Treatment with 50 µM of THC did not cause alterations in cell morphology (figure 28). 
In A, the typical appearance of control (untreated) BeWo cells is presented.  
 
  
  
   
   
Figure 28 - Effects of THC on BeWo cells morphology. (A, B) Phase-contrast microscopy; (C, D) 
Giemsa staining; (E, F) Höechst staining. BeWo cells morphology was analyzed in the absence 
(control) or presence of THC (50 µM) after 24 hours. Results are shown from single representative 
of three independent experiments. 
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On the other hand, cells exposed to WIN (2 µM) exhibited morphological alterations 
(figure 29). In phase contrast microscopy it was possible to observe cytosolic vacuolization, 
whereas chromatin condensation and cytoplasmic vacuoles were observed by Giemsa 
staining. Höechst staining confirmed the presence of chromatin condensation. These 
alterations were accompanied by a reduction in cell density.  
As WIN-treatment induced cytosolic vacuolization, a morphological analysis was 
undertaken in order to clarify their nature. To monitor the formation of acidic vesicular 
organelles (AVOs), BeWo cells were stained with Acridine Orange, a cell-permeable 
acidotropic dye that once protonated gets trapped inside low pH vesicles such as 
autophagosomes and lysosomes, emitting yellow/orange/red fluorescence. Cells were 
observed under a fluorescence microscope and WIN-treated cells presented alterations in 
green fluorescence to orange/red fluoresce, confirming the presence of AVOs (figure 29 G, 
H), which suggests the occurrence of autophagy. Nevertheless, further studies must be 
performed to quantify the increase in the formation of AVOs, as well as the expression of 
biochemical markers.  
As already referred, the endocannabinoid 2-AG was previously analyzed for cell 
viability and, in accordance to those previous studies, a concentration of 10 µM was 
selected. It was possible to observe the presence of chromatin condensation by Giemsa 
and Höechst staining (figure 30).  
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Figure 29 - Effects of WIN on BeWo cells morphology. (A, B) Phase-contrast microscopy; (C, D) 
Giemsa staining; (E, F) Höechst staining; (G, H) Acridine Orange staining. BeWo cells morphology 
was analyzed in the absence (control) or presence of WIN (2 µM) after 24 hours. Arrows represent 
vacuolization (B), chromatin condensation (D) and acid vesicles (H). Results are shown from single 
representative of three independent experiments. 
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Figure 30 - Effects of 2-AG on BeWo cells morphology. (A, B) Phase-contrast microscopy; (C, 
D) Giemsa staining; (E, F) Höechst staining. BeWo cells morphology was analyzed in the absence 
(control) or presence of 2-AG (10 µM) after 24hours. Arrows represent chromatin condensation (D, 
F). Results are shown from single representative of three independent experiments. 
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1.3 Mitochondrial membrane potential  
 
The capacity of the cannabinoids to induce alterations in the mitochondrial membrane 
potential (∆ψm) was assessed by fluorimetry with the probe DiOC6.  All the cannabinoids 
induced similar mitochondrial membrane potential loss. In the case of THC, concentrations 
of 25 µM or 50 µM induced a decrease in ∆ψm around 38%, for 2 µM WIN a decrease of 
33% and for 10 µM 2-AG of 38% (figure 31). 
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Figure 31 - Effect of THC, WIN and 2-AG on BeWo cells mitochondrial membrane potential at 
24h. (A) Changes in mitochondrial membrane potential induced by THC treatment at 25 µM and 50 
µM; (B) WIN treatment at 2 µM; (C) 2-AG treatment at 10µM. CCCP (10 μM) was used as a positive 
control. Results are expressed as mean ± SEM of at least three independent experiments performed 
in triplicate. Significant differences between control and treated cells are denoted as ** (p<0.005) and 
*** (p<0.0005). 
 
Such results suggest that the effects of WIN and 2-AG on cell viability can be 
associated with mitochondrial disfunction. To understand the involvement of CB receptors 
in the observed changes of mitochondrial membrane potential, WIN or 2-AG were treated 
with the CB1 antagonist AM251 (1 µM) and the CB2 antagonist AM630 (1 µM). Since THC 
did not induced changes in cell viability, in this case the studies with the CB antagonists 
were nor performed. 
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CB antagonists did not cause significant reversion of the WIN-induced reduction in 
∆ψm. AM251 caused a reversion of 2.3% and AM630 of 6.3% (figure 32). 
 
 
Figure 32 - Effect of 2 µM WIN on 
BeWo cells mitochondrial 
membrane potential at 24 hours 
in combination with CB 
antagonists. Effect of the addition 
of CB antagonists AM251 and 
AM630 at 1 µM. CCCP (10  μM) was 
used as a positive control. Results 
are expressed as mean ± SEM of at 
least three independent 
experiments performed in triplicate. 
Significant differences between 
control and treated cells are denoted 
as *(p<0.05), ** (p<0.005) and *** 
(p<0.0005). 
 
 
 
 
 
Like in the case of WIN treatments, 2-AG in combination with the CB antagonists 
showed no reversion of the effects caused by 2-AG alone (figure 33). 
 
  
Figure 33 - Effect of 10 µM of 2-
AG on BeWo cells mitochondrial 
membrane potential at 24 hours 
in combination with CB 
antagonists. Effect of the addition 
of CB antagonists AM251 and 
AM630 at 1 µM.  CCCP (10  μM) 
was used as a positive control. 
Results are expressed as mean ± 
SEM of at least three independent 
experiments performed in 
triplicate. Significant differences 
between control and treated cells 
are denoted as *** (p<0.0005). 
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1.4 Reactive oxygen and nitrogen species 
 
To further explore the underlying mechanisms of cell viability loss, it was evaluated 
reactive species production, which is often associated with mitochondrial dysfunction and 
oxidative stress. The ability of the cannabinoids to induce the production of ROS/RNS was 
evaluated by fluorimetry with the probe DCDHF-DA.  
The endocannabinoid 2-AG was the only compound that induced the production of 
ROS/RNS (figure 34 C). The treatment with 10 µM 2-AG induced a 69% increase in 
ROS/RNS generation.  
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Figure 34 - Effect of THC, WIN and 2-AG on BeWo cells ROS/RNS generation. (A) Production 
of ROS/RNS induced by THC at 25 µM and 50 µM; (B) by WIN at 1 µM and 5 µM; (C) by 2-AG at 10 
µM. H2O2 (200  μM) was used as a positive control. Results are expressed as mean ± SEM of at least 
three independent experiments performed in triplicate. Significant differences between control and 
treated cells are denoted as ** (p<0.005) and *** (p<0.0005). 
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The addition of AM251 and of AM630 did not revert significantly the 2-AG-induced 
effect (figure 35). 
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Figure 35 - Effect of 2-AG in combination with the CB antagonists on BeWo cells ROS/RNS 
generation. Production of ROS/RNS induced by 2-AG treatment at 10 µM in the presence of CB 
antagonists AM251 and AM630 at 1 µM. H2O2 (200  μM) was used as a positive control. Results are 
expressed as mean ± SEM of at least three independent experiments performed in triplicate. 
Significant differences between control and treated cells are denoted as *(p<0.05), ** (p<0.005) and 
*** (p<0.0005). 
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1.5 Glutathione levels 
 
Since glutathione plays a critical role in the cellular defense against oxidative and 
nitrosative stress in mammalian cells and 2-AG induced a dramatic increase in ROS/RNS 
production, the ratio between the oxidized and reduced form of glutathione was measured 
after 2-AG treatment. In healthy cells, more than 90% of the total glutathione pool is in the 
reduced form (GSH). When cells are exposed to increased levels of oxidative stress, GSSG 
accumulates and the ratio of GSSG to GSH increases. Thus, an increased ratio of GSSG-
to-GSH is an indication of oxidative stress. The monitoring of reduced and oxidized GSH in 
biological samples is essential for evaluating the redox and detoxification status of the cells 
and tissues against oxidative and free radicals mediated cell injury. 
The preliminary results suggest that the treatment with 10 µM of 2-AG did not seem 
to cause changes in the ratio GSSH/GSH (figure 36). 
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Figure 36 - Preliminary results of the effect of 2-AG (10 µM) on BeWo cells glutathione levels 
at 24 hours. (A) Total glutathione levels (GSH); (B) oxidised form of glutathione (GSSG); (C) 
GSH/GSSG ratio. 
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1.6 CHOP expression 
 
Since 2-AG induces oxidative stress in BeWo cells, we analysed CCAAT-enhancer-
binding protein homologous protein (CHOP) expression by western blot. CHOP is a protein 
that is induced by ER-stress and causes downregulation of the anti-apoptotic protein Bcl-2, 
favouring a pro-apoptotic drive at the mitochondria by proteins that cause mitochondrial 
damage, cytochrome c release and caspase-3 activation. 
Preliminary results showed an increase in CHOP expression after 10 µM 2-AG 
treatment, an effect that appears to be reverted by the co-incubation with the CB2 
antagonist AM630 (figure 37).  
 
 
 
 
Figure 37 - CHOP expression in BeWo cells. Western Blot analysis of CHOP expression in the 
absence (control) or presence of 2-AG (10 µM), and 2-AG (10 µM) co-incubated with the CB 
antagonists AM251 (1 µM) and AM630 (1 µM). β-tubulin was used as loading control. 
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1.7 Cell cycle analysis 
 
A possible mechanism responsible for the observed effects of WIN and 2-AG in cell 
viability reduction is the deregulation of the cell cycle and subsequent alterations in cell 
proliferation. In that way, cell cycle progression was analyzed by flow cytometry after PI 
staining. According to DNA content, cells were distributed to the correspondent cell cycle 
phases. After 24 hours of treatment, 2 µM WIN induced a significant cell cycle arrest in the 
G0/G1 phase (64%), when compared to control cells (51%). Such increase was 
accompanied by a decrease in S phase (10% vs 16% for control) and in G2/M phase (27% 
vs 32%) (figure 38 and 39). 
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Figure 38 - Effects of 2 µM of WIN on BeWo cell cycle progression after 24 hours of treatment. 
Results are expressed as mean ± SEM of at least three independent experiments performed in 
triplicate. Significant differences between control and treated cells are denoted as ** (p<0.005) and 
*** (p<0.0005). 
    
 
Figure 39 - Representative histograms of cell cycle distribution of BeWo cells control and 
treated with 2 µM of WIN for 24 hours. Histograms were obtained with BD Accuri C6 software and 
are representative of one independent assay. The numbers indicate the percentage of cells in each 
cell cycle phase: M15 is the G0/G1 phase, M16 represents the S phase and M17 the G2/M. 
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On the other hand, 10 µM of 2-AG induced a significant cell cycle arrest in the G2/M 
phase (37%), when compared to control cells (32%). This retention may be associated with 
apoptosis. Such increase was compensated by a decrease in S phase (11% vs 16% on 
control) (figure 40 and 41). 
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Figure 40 - Effects of 10 µM of 2-AG on BeWo cell cycle progression after 24 hours of 
treatment. Results are expressed as mean ± SEM of at least three independent experiments 
performed in triplicate. Significant differences between control and treated cells are denoted as 
*(p<0.05). 
 
        
 
Figure 41 - Representative histograms of cell cycle distribution of BeWo cells control and 
treated with 10 µM of 2-AG for 24 hours. Histograms were obtained with BD Accuri C6 software 
and are representative of one independent assay. The numbers indicate the percentage of cells in 
each cell cycle phase: M15 is the G0/G1 phase, M16 represents the S phase and M17 the G2/M. 
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2. Cannabinoid effects in primary cultures of human cytotrophoblasts 
 
The effects of THC, WIN and 2-AG were also evaluated in primary cultures of 
cytotrophoblasts, obtained from human term placentas.  
 
2.1 Mitochondrial membrane potential (∆ψm) 
 
After 24h of treatment, all the compounds induced mitochondrial membrane potential 
loss. Preliminary results showed that THC treatment induced a decrease around 47% in 
∆ψm (figure 42 A) and WIN induced a decrease around 44% (figure 42 B), in comparison 
with the control cells. 2-AG treatment induced a significant decrease of 20% in ∆ψm, 
compared with control (figure 42 C).  
C
on
tr
ol 
25

50 C
C
C
P
0
50
100
150
THC

 m
, 
%
 o
f 
c
o
n
tr
o
l
 
C
on
tr
ol 
2 C
C
C
P
0
50
100
150
WIN-55,212

 m
, 
%
 o
f 
c
o
n
tr
o
l
 
C
on
tr
ol 
10 C
C
C
P
0
50
100
150
***
*
2-AG
*

 m
, 
%
 o
f 
c
o
n
tr
o
l
 
Figure 42 - Effect of THC, WIN and 2-AG on primary cultures of human cytotrophoblasts 
mitochondrial membrane potential at 24 hours. Preliminary results of the changes in 
mitochondrial membrane potential induced by (A) THC treatment (25 µM and 50 µM); (B) WIN 
treatment (2 µM); (C) 2-AG treatment (10 µM) CCCP (10  μM) was used as a positive control. Results 
are expressed as mean ± SEM of at least three independent experiments performed in triplicate. 
Significant differences between control and treated cells are denoted as **(p<0.005), and *** 
(p<0.0005). 
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Although preliminary data, this results suggest that, in CT, THC and WIN treatment 
lead to similar consequences to the ones observed in BeWo cells. Since 2-AG proved to 
induce apoptosis in BeWo cells, its effects were explored in CTs. 
In combination with 2-AG, AM251 restored the ∆ψm in 11% and AM630 induced a 
significant reversion of 15% (figure 43). 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 43 - Effect of 2-AG in combination with CB antagonists on primary cultures of human 
cytotrophoblast cells mitochondrial membrane potential at 24 hours. Changes in mitochondrial 
membrane potential induced by 2-AG treatment (10µM) and in combination with the CB antagonists 
AM251 and AM630 (1µM). CCCP (10 μM) was used as a positive control. Results are expressed as 
mean ± SEM of at least three independent experiments performed in triplicate. Significant differences 
between control and treated cells are denoted as ** (p<0.005) and *** (p<0.0005). Significant 
differences between 10µM 2-AG-treated cells and 2-AG (10µM) in combination with AM630 are 
denoted as #(p<0.05). 
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2.2 Reactive oxygen and nitrogen species 
 
2-AG was the only cannabinoid that showed to induce in BeWo cells an increase in 
reactive species generation. In the case of CTs, 2-AG induced an increase of 46% in 
ROS/RNS generation, compared with control cells, though no reversion was observed when 
the cells were co-treated with the CB antagonists AM251 and AM630 (figure 44).  
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Figure 44 - Effect of 2-AG on primary cultures of human cytotrophoblasts ROS/RNS 
generation. Production of ROS/RNS induced by 2-AG treatment (10 µM) and in co-incubation with 
the CB antagonists AM251 and AM630 (1 µM). H2O2 (200 μM) was used as a positive control. Results 
are expressed as mean ± SEM of at least three independent experiments performed in triplicate. 
Significant differences between control and treated cells are denoted as *** (p<0.0005). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cannabinoids impact on pregnancy: effects in trophoblast cells 
 
| Results 
 
 
68 
 
2.3 Morphological studies 
 
 
The morphology of hCT was also analyzed, to understand if the features of apoptosis 
were present in these cells. Giemsa and Höechst staining showed condensation of 
chromatin after 24 hours of 2-AG treatment (figure 45). The results obtained in CT cells 
were in accordance with the results in BeWo cells. 
 
  
 
  
 
   
 
Figure 45 - Effects of 2-AG on primary cultures of human cytotrophoblasts morphology. (A, 
B) Phase-contrast microscopy; (C, D) Giemsa staining; (E, F) Höechst staining. BeWo cells 
morphology was analyzed in the absence (control) or presence of 2-AG (10 µM) after 24 hours. 
Arrows represent chromatin condensation (D, F). Results are shown from single representative of 
three independent experiments. 
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2.4 CHOP expression 
 
Since CHOP expression seemed to be enhanced in BeWo cells after 24 hours of 2-
AG (10µM) treatment, we investigated if the same occurred in CTs. Again, a preliminary 
result an increase in the expression of this ER-stress-related protein. The effect was also 
reversed by co-incubation with the CB antagonists, although the reversion appears to be 
more significant when cells were co-incubated with AM630 (figure 46). 
 
 
Figure 46 - CHOP expression in primary cultures of human cytotrophoblasts. Western Blot 
analysis of CHOP expression in the absence (control) or presence of 2-AG (10 µM), and 2-AG (10 
µM) co-incubated with the CB antagonists AM251 (1 µM) and AM630 (1 µM). β-tubulin used as 
loading control. 
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2.5 Caspase 3/7 activity 
 
In order to clarify the involvement of apoptosis in 2-AG-mediated effects, caspase 3/7 
activity was measured. A preliminary result showed an increase in caspases activity after 
24 hours of 2-AG treatment. At 10 µM, 2-AG induced an increase of around 33% on caspase 
3/7 activity, an effect that was partially reversed by co-incubation with AM251 and AM630, 
which resulted in 7% and 12% of reversion (figure 47). 
 
C
on
tr
ol 
10
+A
M
25
1

10
+A
M
63
0

10
S
TS
ZV
A
D
0
50
100
150
200
2-AG
L
u
m
in
e
s
c
e
n
c
e
, 
%
 o
f 
c
o
n
tr
o
l
 
Figure 47 - Effect of 2-AG on primary cultures of human cytotrophoblasts caspase 3/7 activity 
at 24 hours. Changes in caspase 3/7 activity induced by 24 hours of 2-AG treatment at 10 µM and 
in combination with the CB antagonists AM251 and AM630 at 1 µM. ZVAD (10  μM)  was used as a 
negative control and STS (100 nM) was used as a positive control.  
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During placental development, trophoblast cells undergo highly regulated processes 
of proliferation, apoptosis and differentiation. Proliferation of CTs is followed by 
differentiation of daughter cells that have left the cell cycle. Then, syncytial fusion of highly 
differentiated CTs with the overlying ST occurs. Within the ST, further differentiation and 
maturation takes place, leading to aging and late apoptosis of nuclei and other organelles 
at specific sites [261, 262]. Regulation of apoptotic processes is not only important for 
programmed morphogenesis, but also suggestively involved in syncytium formation, being 
of significant relevance to the biology of early placental villi in general [263]. The balance of 
the dynamics between apoptosis, proliferation and differentiation is a hallmark of 
developmental regulation and the key to normal development of the villous tree. Any high 
dimensional error in this balance may predispose villous growth to anomaly and/or 
insufficiency [264]. Hence, any changes that interfere with the delicate process of turnover 
of trophoblast cells may compromise pregnancy success and lead to some pregnancy-
associated disorders. A large number of cytokines, growth factors and steroid hormones 
participate in these processes and endocannabinoids may be important players in this 
cytokine network.  
During pregnancy, the placenta and the fetus become frequently exposed to drugs of 
abuse such as cannabinoids because of maternal consumption of these substances. This 
may cause disturbances on cannabinoid signaling and on the ECS homeostasis. Thus, the 
aim of this work was to explore the effects of phyto-, synthetic and endocannabinoids in 
cytotrophoblasts, to clarify the impact of cannabinoid compounds in placentation. 
In this study the results showed that the main psychoactive compound of the cannabis 
plant, THC, did not affect BeWo cells viability. This phytocannabinoid did not induce the 
formation of reactive species of oxygen/nitrogen but caused a decrease in mitochondrial 
membrane potential. However, recently, our group reported that THC has a dual effect in 
primary cultures of human trophoblasts: enhancing MTT metabolism at low concentrations, 
whereas at higher doses decreased cell viability. The prevention of trophoblast cell death 
seems to result from an antioxidant effect, as showed by the decrease in the generation of 
ROS/RNS. Moreover, THC impaired CTs syncytialization [251]. The antioxidant properties 
of THC and other phytocannabinoids were also reported by Chen and Buck as THC 
prevented serum-deprived oxidative cell death in B lymphoblastoid cells and fibroblasts. 
[265]. On the other hand, Khare et al. reported that THC inhibits cell proliferation and 
activates a restricted tight transcriptional program in the BeWo cells, modulating genes 
encoding for cell morphology, growth and apoptosis [266]. THC ability to induce apoptosis 
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has been described in several types of cancer cells, as in the case of prostate PC-3 cells 
via a receptor-independent mechanism [267] and in melanoma cells, by activation of an 
autophagic-mediated apoptosis [193]. Besides the suggested interference with trophoblast 
turnover, during pregnancy, THC may also interfere with nutrient transport across the 
placenta. Keating et al. reported that chronic exposure to THC decreased folic acid uptake, 
a micronutrient that is particularly important during pregnancy for normal placental and fetal 
development [268].  
The synthetic cannabinoids emerged in recent years as drugs of abuse and little is 
known about their effects in general and particularly in reproductive health. In this work, the 
synthetic cannabinoid WIN was able to induce a dose-dependent loss of cell viability that 
was evident at lower concentrations than the other studied cannabinoids. MTT results 
revealed that WIN at 2 µM was able to decrease cell viability and, at this concentration, no 
significant LDH release was detected, indicating that cell viability loss was not due to a 
necrotic process of cell death. To explore the WIN-induced loss of cell viability mechanisms, 
it was evaluated the mitochondrial membrane potential which was decreased, without the 
involvement of ROS/RNS production. This suggests that mitochondrial events might be 
involved. Indeed, this compound induced mitochondrial depolarization in other cell models, 
such as glioma cells [269] and hepatoma cells [270]. In glioma cells, WIN induced a down-
regulation of Akt and Erk signaling, activation of caspases and a decrease in the levels of 
phosphorylated Bad [269]. In hepatoma HepG2 cells, it was also observed a mitochondrial 
depolarization accompanied by down-regulation of survival factors and, associated with 
JNK/p38 MAPK pathway activation [270]. Nevertheless, the observed loss of cell viability 
induced by the cannabinoids under study may be due to antiproliferative effects. In this way, 
cell cycle analysis was studied by flow cytometry. The results revealed a cell cycle arrest in 
G0/G1 after WIN treatment. These results are in accordance to the reports in other cell 
models. In human prostate cancer cells, treatment with WIN for 24 hours resulted in cell 
cycle arrest in the G0/G1 phase, which seems to be due to ERK1/2 activation, subsequently 
leading to an induction of apoptosis [271]. Park et al., in a study performed in gastric cancer 
cells, showed that WIN reduced cell proliferation, via G0/G1 phase cell cycle arrest, which 
preceded apoptosis and was mediated via activation of MAPK pathway and activation of 
pAKT [272]. In human breast cancer cells,  WIN blocks tumor growth by inducing cell cycle 
arrest in G0/G1 and apoptosis through a CB-dependent manner [273].  
The results of morphological analysis revealed that, after treatment with WIN, BeWo 
cells presented a marked cytoplasmic vacuolization and chromatin condensation. Notaro et 
al. also observed similar morphological alterations in osteosarcoma cells. In their study, 
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WIN induced a G2/M phase cell cycle arrest, associated with the induction of the main 
markers of ER-stress (GRP78, CHOP and TRIB3), conversion of LC3-I into LC3-II and the 
enhanced incorporation of monodansylcadaverine and acridine orange, two markers of the 
autophagic compartments such as autolysosomes [197]. In a study performed in mantle cell 
lymphoma a massive vacuolization was also observed after WIN treatment but, in this case, 
the persistent expression of mammalian homolog of Atg8 with microtubule-associated LC3-
II and p62, as well as the lack of protection from the autophagic inhibitor chloroquine, 
indicated that lysosomal degradation was not involved in this cytoplasmic vacuolization 
[274]. In decidual fibroblasts, stimulation of CB1 by WIN led to a decrease in intracellular 
cAMP levels and to an increase in DNA fragmentation and caspase-3 levels, suggesting a 
stimulation of apoptosis by this cannabinoid and an interference with the decidualization 
[275]. 
Depending on the system, though the majority of studies point to an antiproliferative 
effect of WIN, which is of great interest for the treatment of cancer, this compound can also 
have neuroprotective properties. In dentate gyrus granule cells, WIN showed to have 
neuroprotective properties, by acting upon CB1 receptors and, at higher concentrations, 
also other receptors were activated [276]. In our study, the effects were not reverted by the 
co-incubation with the CB1 and CB2 antagonists, AM251 and AM630, respectively. This 
observation suggest that WIN effects may be CB-independent and other signaling pathways 
can be involved. 
Following previous works from the group, the effects of the endocannabinoid 2-AG 
were explored. Costa et al.  have previously observed that  this compound was able to 
decrease cell viability, inducing apoptosis in BeWo cells [129] and impair CTs 
syncytialization, interfering with pregnancy-related hormones expression, such as chorionic 
gonadotropin and leptin [238]. The results demonstrate that, in contrast with the other 
studied cannabinoids, 2-AG was able to increase ROS/RNS generation in both BeWo cells 
and hCTs, suggesting that the mechanism of 2-AG action may involve oxidative stress. This 
could be of great relevance, since placenta develops in a state of hypoxia, and any oxidative 
changes may disturb homeostasis. Moreover, mitochondrial membrane potential was also 
affected by 2-AG treatment, which could be associated with early apoptotic events. The 
effect on mitochondrial membrane potential was partially reversed by the addition of the 
CB2 antagonist AM630 in CT. In accordance with our findings, 2-AG also induced death of 
hepatic stellate cells via mitochondrial reactive oxygen species, accompanied by 
mitochondrial depolarization [277]. Accumulating evidence suggests that protein folding and 
generation of ROS as a byproduct of protein oxidation in the ER are closely linked events. 
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It has also become apparent that activation of the unfold protein response (a highly specific 
ER quality-control system) on exposure to oxidative stress is an adaptive mechanism to 
preserve cell function and survival. Persistent oxidative stress and protein misfolding initiate 
apoptotic cascades [278, 279]. CHOP is induced by ER-stress and causes downregulation 
of the anti-apoptotic protein Bcl-2, favoring a pro-apoptotic drive at the mitochondria by 
proteins that cause mitochondrial damage, cytochrome c release and caspase-3 activation 
[280]. To deeply explore ER-stress involvement in 2-AG actions, it was analyzed the 
expression of the ER-stress-related protein CHOP and it was observed an increase in 
CHOP expression after treatment. The co-incubation with AM630 reversed the effects on 
both BeWo and hCT cells, suggesting that 2-AG effects relies on CB2 activation. Moreover, 
the preliminary results in CTs indicate an activation of the executioner caspases-3/7, 
supporting an apoptotic process of cell death. Additionally, the analysis of DNA content by 
flow cytometry showed that 2-AG-treated cells presented an increase in the population in 
G2/M phase, which was already described to be related with apoptosis [281].  
Our results highlight the importance of eCBs in cytotrophoblast cell apoptosis and 
suggest that deregulation of ECS may interfere with normal trophoblat turnover. 
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Final conclusions 
 
The work developed in the scope of this master’s thesis compares the effects of three 
different types of cannabinoids in cytotrophoblast cells. The phytocannabinoid THC did not 
affect cell viability in the studied conditions, in contrast with the synthetic cannabinoid WIN 
that was able to decrease cell viability at low concentrations. No changes in the oxidative 
state were detected, but WIN induced mitochondrial membrane depolarization, cell cycle 
arrest in G0/G1 phase and morphological changes suggesting that autophagy may take part 
in the observed loss of cell viability. Following our previous results reporting 2-AG induced-
apoptosis in BeWo cells it was observed a decrease in mitochondrial membrane potential 
associated to ROS/RNS generation. Endoplasmic reticulum stress may be involved, as 
preliminary results point to an increase in CHOP expression. In addition, 2-AG  induced cell 
cycle alterations causing a G2/M phase cell cycle arrest.  
This work demonstrates that, in placenta, cannabinoids may interfere with important 
processes of cell proliferation and cell death. Understanding the effects of cannabinoid 
compounds in human reproduction, more specifically in women fertility is urgent, since 
cannabis and derivates are the most consumed illicit drugs worldwide and some of the most 
consumed recreational drugs by pregnant women. The consumption of such drugs may 
alter the ECS balance, ultimately interfering with eCB levels, and leading to pregnancy 
complications and infertility. So, the knowledge about ECS, cannabinoid signaling and 
cannabinoids effects in placental cells may help to disclose the cellular mechanisms behind 
some pregnancy-related disorders and ultimately be used to design future treatments for 
infertility. 
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